Bioinformatic approaches to augment study of epithelial - to - mesenchymal transition in lung cancer Tim N . Beck , 1 , 4 Adaeze J . Chikwem , 1 , 3 Nehal R . Solanki , 2 , 5 and Erica A . Golemis 1 , 3 , 4 1 Developmental Therapeutics Program , Fox Chase Cancer Center , Philadelphia , Pennsylvania ; 2 Immune Cell Development and Host Defense Program , Fox Chase Cancer Center , Philadelphia , Pennsylvania ; 3 Temple University School of Medicine , Philadelphia , Pennsylvania ; and 4 Program in Molecular and Cell Biology and Genetics , Drexel University College of Medicine , Philadelphia , Pennsylvania ; and 5 Program in Microbiology and Immunology , Drexel University College of Medicine , Philadelphia , Pennsylvania Submitted 15 May 2014 ; accepted in ﬁnal form 4 August 2014 Beck TN , Chikwem AJ , Solanki NR , Golemis EA . Bioinformatic ap - proaches to augment study of epithelial - to - mesenchymal transition in lung cancer . Physiol Genomics 46 : 699 – 724 , 2014 . First published August 5 , 2014 ; doi : 10 . 1152 / physiolgenomics . 00062 . 2014 . —Bioinformatic approaches are in - tended to provide systems level insight into the complex biological processes that underlie serious diseases such as cancer . In this review we describe current bioinformatic resources , and illustrate how they have been used to study a clinically important example : epithelial - to - mesenchymal transition ( EMT ) in lung cancer . Lung cancer is the leading cause of cancer - related deaths and is often diagnosed at advanced stages , leading to limited therapeutic success . While EMT is essential during development and wound healing , pathological reactivation of this program by cancer cells contributes to metastasis and drug resistance , both major causes of death from lung cancer . Challenges of studying EMT include its transient nature , its molecular and phenotypic heterogeneity , and the complicated networks of rewired signaling cascades . Given the biology of lung cancer and the role of EMT , it is critical to better align the two in order to advance the impact of precision oncology . This task relies heavily on the application of bioinformatic resources . Besides summarizing recent work in this area , we use four EMT - associated genes , TGF - (cid:2) ( TGFB1 ) , NEDD9 / HEF1 , (cid:2) - catenin ( CTNNB1 ) and E - cadherin ( CDH1 ) , as exem - plars to demonstrate the current capacities and limitations of probing bioinformatic resources to inform hypothesis - driven studies with therapeutic goals . bioinformatics ; cancer ; epithelial - to - mesenchymal transition ; EMT ; NEDD9 / HEF1 ; E - cadherin ; SRC ; TGF - (cid:2) ; (cid:2) - catenin ; genomics ; proteomics ; sequencing ; precision oncology The Rising Value of Bioinformatics in Cancer Research With the increasing use of high - throughput approaches , and after decades of study of molecular mechanisms , it is now apparent that many forms of cancer are associated with a plethora of genetic ( 113 ) and epigenetic alterations ( 246 ) . Despite many recent technological advances ( 61 ) , and 40 years after cancer DNA sequencing has come into existence ( 215 ) , the scientiﬁc community is still optimizing approaches of data acquisition and interpretation ( 5 , 324 , 336 ) . As an interdisci - plinary ﬁeld in which biological , statistical , and computational sciences converge ( 324 ) , bioinformatics provides essential sup - port for ‘ - omics’ - driven studies ( 284 ) . The access to online repositories and web - based algorithms ( Table 1 ) has made it possible to rapidly screen for global and speciﬁc changes in gene and protein expression levels as well as genetic alterations ( e . g . , mutations and translocations ) that are unique and some - times essential to cancer cells ( 21 , 113 ) . For individual inves - tigators , scrutiny of resources containing DNA , protein , and RNA expression data from cell lines , model organisms , and patient samples can enlarge and enhance initial experimental datasets . Subsequent analysis of databases that assign func - tional annotations to genes [ e . g . , Unigene ( 346 ) and GenBank ( 26 ) ] and proteins [ e . g . , UniProt ( 125 ) , PDB ( 30 ) , and PFAM ( 243 ) ] , and the association of these elements in signaling networks [ KEGG ( 146 ) , Reactome ( 65 ) , and others ( 174 ) ] can assist in the integration of data ( Fig . 1 ) . Precision oncology ( 21 , 101 ) , or individualized cancer treat - ment guided by - omics data , is dependent on the ability of clinicians to put vast data in a context that allows selection of appropriate therapies . Hence , there is a great need to develop analytic paths that integrate bioinformatic resources to consider the entire system of a tumor . In this review , we describe how bioinformatic approaches can support the study of lung cancer , a type of cancer with great genetic variability ( 145 ) and pressing need for better treatments . We particularly address the topic of epithelial - to - mesenchymal transition ( EMT ) , a signal - ing and morphological shift associated with tumor metastasis Address for reprint requests and other correspondence : E . A . Golemis , Fox Chase Cancer Center , 333 Cottman Ave . , Philadelphia , PA 19111 ( e - mail : Erica . Golemis @ fccc . edu ) . Physiol Genomics 46 : 699 – 724 , 2014 . First published August 5 , 2014 ; doi : 10 . 1152 / physiolgenomics . 00062 . 2014 . Review 1094 - 8341 / 14 Copyright © 2014 the American Physiological Society 699 b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m Table 1 . Bioinformatics resources Resource Description Location Ref . No . Genomic Analysis and Visualization Babelomics integrative platform designed to analyze panomics data http : / / www . babelomics . org 193 GEPAS Analysis Tool web - based packages for microarray data analysis http : / / www . gepas . org 295 GenePattern analysis pipeline to process gene expression data , proteomics , SNP analysis , ﬂow cytometry , RNA - seq http : / / www . broadinstitute . org / cancer / software / genepattern 63 , 248 Gene Set Enrichment Analysis ( GSEA ) computational determination of statistically signiﬁcant gene expression differences between different biological states http : / / broad . mit . edu / gsea 199 , 290 Genomica software tool to analyze , integrate and visualize RNA / DNA data http : / / genomica . weizmann . ac . il 25 , 268 Geo2R compare two or more groups in terms of gene expression http : / / www . ncbi . nlm . nih . gov / geo / geo2r 17 InSilico DB Genomic Datasets Hub web - based platform to analyze genomic datasets https : / / insilicodb . com / 63 Integrative Genomics Viewer visualization tool for large genomic datasets http : / / www . broadinstitute . org / igv / home 255 , 301 Integrative Platforms Bioconductor ( R statistical language ) bioinformatics software for the analysis of genomic data http : / / www . bioconductor . org / 166 , 167 GenomeSpace cloud - based platform that accesses bioinformatics tools http : / / www . genomespace . org / 256 SAGE / Synapse platform to share , aggregate and describe research https : / / www . synapse . org / 96 Genomics and Transcriptomics cBioPortal visualization and analysis of cancer genomics datasets http : / / www . cbioportal . org / public - portal 47 , 99 COSMIC : Catalogue of Somatic Mutations in Cancer stores and displays a comprehensive dataset of somatic mutation information and related details http : / / cancer . sanger . ac . uk / cancergenome / projects / cosmic 89 Expression Atlas microarray and RNA - seq data http : / / www . ebi . ac . uk / gxa / home 148 , 231 My Cancer Genome web - based platform that integrates genomic information , available therapeutics and ongoing clincal trials http : / / www . mycancergenome . org / 291 Oncomine genomics information and expression proﬁles for different cancer types and cancer cell lines https : / / www . oncomine . org / resource / login . html 252 The Cancer Genome Atlas ( TCGA ) portal to access , search , download and analyse datasets http : / / cancergenome . nih . gov 59 , 60 Cell Lines / Pharmacogenomics Cancer Cell Line Encyclopedia ( CCLE ) comprehensive analysis and detailed characterization http : / / www . broadinstitute . org / ccle / home 16 ComparativeToxicogenomicsDatabase ( CTD ) curated database on toxicogenomic interactions http : / / ctdbase . org 70 PharmacogenomicsKnowledgebase ( PharmGKB ) curated database focused on pharmacogenomics ( i . e . , how genetic variation affects drug response ) http : / / www . pharmgkb . org 331 The Genomics of Drug Sensitivity in Cancer ( GDSC ) cancer cell line - based predication of responses to anticancer drugs ; focuses on compounds and cancer genes http : / / www . cancerrxgene . org 342 Pathways and Networks Cytoscape software platform to visualize and analyze complex interaction networks http : / / cytoscape . org / index . html 174 , 273 GeneMania web - based platform used to identify associations of input genes with additional genes as part of a network http : / / www . genemania . org 349 Kyoto Encyclopedia of Genes and Genomes ( KEGG ) database resource with focus on high - level functions of biological systems as well as comprehensive pathway maps http : / / www . kegg . jp 147 Continued Review 700 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m and poor response to therapy [ Fig . 2 ; ( 221 ) ] . We discuss both positive uses of bioinformatic approaches to augment our understanding of these processes and current weaknesses that must be overcome to maximize the value of this form of analysis . Lung Cancer and EMT Lung cancer is the leading cause of cancer - related mortality for both men and women worldwide . The majority of lung cancer patients present late in their disease course , with only 15 % of cases diagnosed at a localized stage ( 4a ) . Nonsmall cell lung cancer ( NSCLC , the most common form of lung cancer ) has a 5 yrsurvival rate of (cid:3) 15 % , with metastasis as the primary cause of death ( 341 ) . Classic treatments for NSCLC include surgery , chemotherapy , and chemoradiation ( 85 ) . While these treatments are often effective in improving sur - vival , they are also associated with signiﬁcant toxicities in patients ( 36 , 54 , 84 ) . With the advent of next - generation sequencing , a more comprehensive understanding of the molecular pathogenesis of lung cancer has been achieved ( 61 ) , offering the hope of more effective and less toxic therapies . NSCLC , typically associated with a history of tobacco use , has been shown to have one of the highest frequencies of mutations among the different can - cer types ( 144 , 145 , 337 ) . Work of The Cancer Genome Atlas ( TCGA ) consortium and the International Cancer Genome Consortium has highlighted the many different potential driver and passenger mutations in lung cancer ( 145 , 197 ) . Some of the driver mutations are directly actionable [ i . e . , activate proteins or pathways that can be targeted therapeutically to block tumor growth ( 202 ) ] . In the case of NSCLC , valuable protein - targeted therapeutic regimens include drugs inhibiting the epidermal growth factor receptor ( EGFR ) , expressed in 60 % of NSCLC and frequently mutated ( 68 , 282 ) . Also , for a subset of NSCLC tumors , drugs such as crizotinib or ceritinib that speciﬁcally target EML4 - ALK [ a fusion protein combining echinoderm microtubule - associated protein - like 4 ( EML4 ) and anaplastic lymphoma kinase ( ALK ) ] have been developed . Some of the available targeted therapeutics are now used as ﬁrst - line ther - apeutic agents ( 45 , 56 , 93 , 276 ) . To add an additional layer of complexity , lung cancer commonly involves mutations inactivating tumor suppres - sors , which are generally not therapeutically actionable . TP53 is the most commonly mutated tumor suppressor in lung cancer ( 135 ) , followed by the serine / threonine kinase LKB1 ( 270 ) . Despite some improvements in clinical out - comes from targeted therapies , the impact on overall sur - vival rates has thus far been limited ( 128 , 150 ) . This reﬂects the ability of tumor cells to compensate for inhibition of speciﬁc driver proteins ( 105 ) . In addition , many mutations occurring in NSCLC are currently considered “passenger” mutations . Passenger mutations do not drive tumorigenesis ( 322 ) ; however , some of these mutations can impact disease progression and therapeutic response ( 190 ) . One way to target tumor growth more effectively may be to focus on pathological processes speciﬁcally associated with Table 1 . — Continued Resource Description Location Ref . No . Pathguide comprehensive list of biological pathway related resources http : / / www . pathguide . org 12 Reactome pathway browser to visualize and interact with signaling pathway http : / / www . reactome . org 65 STRING ( Search Tool for the Retrieval of InteractingGenes / Proteins ) web - based platform to identify protein - protein interactions http : / / string - db . org 91 Proteomics Focused Assisted Model Building with Energy Reﬁnement software package to conduct molecular dynamics simulations http : / / ambermd . org / 257 Human Protein Reference Database information on human proteins http : / / www . hprd . org / 151 NetworkKin web - based application to predict kinase - substrate interactions http : / / networkin . info / version _ 2 _ 0 / search . php 173 PFAM database of protein families with focus on functional domains http : / / pfam . sanger . ac . uk 243 PhosphoELM phosphorylation database with data extracted from literature and phosphoproteomics analyses http : / / phospho . elm . eu . org 75 PhosphoPoint comprehensive human interactome of kinases and phosphoproteins http : / / kinase . bioinformatics . tw 339 UniProt resource for protein sequences and function http : / / www . uniprot . org / 8 General Databases GenBank NIH genetic sequence database https : / / www . ncbi . nlm . nih . gov / genbank 27 Molecular Signatures Database ( MsigDB ) collection of annotated gene sets that are searchable and that can also be downloaded http : / / www . broadinstitute . org / gsea / msigdb / index . jsp 290 NCBI Homologene construction of homology groups http : / / www . ncbi . nlm . nih . gov / homologene 210 Unigene provides extensive information on transcripts http : / / www . ncbi . nlm . nih . gov / unigene 210 Review 701 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m cancer mortality ( 137 , 324 ) and to disrupt protein interaction hubs central to a given process ( 137 ) . Metastatic disease is the primary cause of lung cancer - related mortality ( 341 ) , and for many tumors it is at least partially dependent on EMT ( 170 , 213 , 237 ) , although EMT is not the only mechanism of me - tastasis ; for example , some tumors use a different dispersion pattern , by amoeboid movement of individual cells ( 260 ) . Importantly , tumor cells that have undergone EMT also pos - sess many features of cancer stem cells ( 184 , 229 , 263 , 265 ) and are often therapy resistant ( 6 , 40 , 50 , 67 , 194 ) . These features make EMT a process of high interest as a therapeutic target to improve clinical management of lung cancer . Both intrinsic and extrinsic factors initiate EMT in subsets of primary epithelial tumor cells [ evidence suggests single cells or clusters of cells ( 344 ) ] , typically at the tumor margins ( 329 ) . Although normal and necessary during embryonic develop - ment and during wound healing ( 214 ) , activation of EMT in the malignant neoplastic setting permits tumors to invade surrounding tissue and metastasize to distant locations ( 37 , 64 , 340 ) . EMT is not an “all - or - nothing” process , and the roles of EMT in single cells versus in collective cell migration are topics of considerable debate ( 57 , 95 , 109 , 271 ) . Following initiation , cells ﬁrst enter a partial EMT state ( 34 , 53 , 228 , 261 ) , during which cells are quasi - epithelial and quasi - mesen - chymal [ Fig . 2 A ; ( 293 ) ] . Several studies suggest that prior to or during intravasation , the mesenchymal state is assumed , sup - porting entry of individual tumor cells into blood vessels ( 251 , 311 , 312 , 344 ) . Alternatively , intravasation has been observed for cell clusters , potentially with or without lead cells that have undergone partial EMT ( 57 , 95 , 271 ) . Compatible with the idea of group migration , circulating groups of clustered tumor cells have been found in peripheral blood samples ( 120 , 127 ) . Intravasation is followed by dissemination and eventual ex - travasation at distant sites ( 251 , 311 ) . For mesenchymal - like cells , once distant sites are reached , mesenchymal - to - epithelial transition [ MET ; a process also essential during development ( 176 , 214 , 298 ) ] is required to allow cells to colonize tissue and form macrometastasis [ Fig . 2 A ; ( 143 , 214 , 224 , 315 ) ] . The timing of EMT / MET transition is not well established . Several studies provide evidence for both epithelial and mesenchymal circulating tumor cells , as well as cells expressing markers for both phenotypes ( 9 , 169 , 344 ) . Fig . 1 . Bioinformatics organizes the bench - to - bedside dialog . In workﬂow using bioinformatic tools , there is typical extensive back and forth between informational databases , experimental work , and clinical practice . Parts of the ﬁgure were adapted from Servier Medical Art ( http : / / www . servier . com / content / servier - medical - art - now - licensed - under - creative - commons ) . Review 702 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m EMT is controlled by multiple intrinsic and extrinsic factors [ e . g . , hypoxia , inﬂammation and cytokines ( 142 , 170 ) ] , which cooperative to regulate gene expression ( 163 ) , also integrating information about the microenvironmental context of tumor cells [ Fig . 2 B ; ( 2 , 239 , 324 ) ] . Intrinsically , there are several commonly used molecular markers for EMT , which include decreased expression of the epithelial marker protein E - cad - herin ( 143 , 215 , 347 ) ; increased expression of the mesenchy - mal markers N - cadherin ( CDH2 ) and vimentin ( VIM ) ( 200 ) ; nuclear localization of (cid:2) - catenin ( 172 ) ; and increased produc - tion of the transcription factors ( TF ) SNAI1 ( Snail ) ( 44 ) , SNAI2 ( Slug ) ( 323 ) , TWIST1 ( 340 ) , EF1 / ZEB1 ( 102 ) , SIP1 / ZEB2 ( 258 ) , and / or E47 ( 66 ) , which control the expression of E - cadherin and other proteins reprogrammed in EMT ( 163 , 297 , 318 ) ( Fig . 2 ) . An extended list of EMT - associated mo - lecular markers has been recently proposed ( 163 ) . A complicated network of signaling cascades inﬂuences regulation of EMT markers and transcription factors . Multiple collaborating pathways , modulated by paracrine and autocrine signaling , activate EMT ( 263 ) . The main known signaling hubs include the transforming growth factor ( TGF ) - (cid:2) superfamily , Wnts , Notch , Sonic hedgehog ( Shh ) , hepatocyte growth factor ( HGF ) , ﬁbroblast growth factor ( FGF ) , epidermal growth fac - tor ( EGF ) , c - Met , and others ( 103 , 188 , 203 , 215 , 238 , 299 , 308 ) . Scaffolding proteins including NEDD9 , p130CAS , DAB2IP , and GRASP / Tamalin also support EMT ( 11 , 41 , 216 , 335 ) , as these proteins frequently bring together EMT - related signaling pathways . In the case of NEDD9 , TGF - (cid:2) and Wnt for example are two signaling cascades heavily reliant on the scaffolding protein for proper function ( 171 , 201 , 216 ) . EMT also involves changes in intracellular regulatory pro - cesses such as mRNA splicing ( 275 ) . EMT - associated changes in splicing patterns are induced by downregulation of two key proteins , epithelial splicing regulatory protein 1 and 2 ( ESRP1 and ESRP2 ) , affecting numerous transcripts ( 326 , 327 ) . EMT - associated gene splice variants have been described for A B Fig . 2 . Epithelial - to - mesenchymal transition ( EMT ) : common features and signaling events . A : the gradual progression of cancer cell metastasis involving EMT and mesenchymal - to - epithelial transition ( MET ) , with listed markers of the epithelial and mesenchymal phenotypes ( 143 , 214 , 215 , 293 , 298 ) . B : EMT is controlled by many extrinsic and intrinsic factors . Cytokines found in the tumor microenvironment , such as transforming growth factor ( TGF ) - (cid:2) ( TGFB1 – 3 ) , are crucial regulators of this process ( 88 , 134 , 209 , 292 ) . First , TGF - (cid:2) activates SMAD2 and SMAD3 , which complex with SMAD4 ( 277 ) . This trimeric SMAD complex then translocates to the nucleus where it can activate the expression of EMT inducing transcription factors ( 19 , 277 ) . SMAD6 / 7 regulate SMAD signaling by inhibiting the phosphorylation of SMAD2 / 3 ( 188 ) . Second , TGF - (cid:2) activates AKT through PI3K ; many receptor tyrosine kinases ( RTKs ) can also active AKT . The activation of AKT has various proliferative effects , including inhibition of (cid:2) - catenin degradation by blocking GSK3B , which leads to an accumulation of (cid:2) - catenin in the cytoplasm and subsequent translocation into the nucleus ( 119 , 124 , 182 , 236 ) . (cid:2) - Catenin is a direct binding partner of E - cadherin and is critical for proper adhesion ( 236 , 319 ) . E - cadherin cleavage frequently induces (cid:2) - catenin release from the adhesion complexes , freeing it for downstream signaling . (cid:2) - Catenin - dependent signaling can also be limited by the Axin and APC destruction complex and marked for proteosomal degradation . However , active Wnt signaling disrupts the destruction complex , causing accumulation of (cid:2) - catenin in the cytoplasm , followed by translocation to the nucleus and interaction with TCF / LEF to induce transcription of target genes relevant to EMT ( 143 , 317 ) . Third , through the activation of the RHOA , TGF - (cid:2) signaling leads to many cytoskeletal changes , which promote the mesenchymal phenotype and enhance cell motility ( 205 , 272 ) . The scaffolding protein NEDD9 initiates activation of FAK through direct interaction . FAK activation subsequently results in the phosphorylation of NEDD9 , to recruit effector proteins Crk and Crk - L , leading to activation of the migratory machinery and an invasive phenotype ( 222 , 304 ) . NEDD9 interacts physically with TGF - (cid:2) effector proteins SMAD3 and SMAD6 / 7 to modulate their activity ( 136 ) . Phosphorylated NEDD9 also physically interacts with SRC ( 10 , 303 ) . Last , NEDD9 forms a complex with DOCK3 , leading to RAC activation and initiation of mesenchymal like cell movement ( 259 ) . Noncoding microRNAs also control EMT through transcriptional repression of genes governing epithelial identity ( 162 , 348 ) . The miR - 200 family members directly target ZEB1 and ZEB2 . During EMT these microRNAs are downregulated , resulting in an increase in ZEB1 / 2 , thus promoting initiation of the mesenchymal transition ( 117 , 227 , 266 ) . Hypoxia is also a major EMT inducer due to its suppressive activity on E - cadherin ( 140 , 333 , 340 ) . Review 703 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m FGFR2 , RON1 , (cid:2) - catenin , CD44 , and others ( 326 ) . Noncoding microRNAs also control EMT through transcriptional repres - sion of genes governing epithelial identity ( 162 , 348 ) . One of the best - studied families of EMT - associated microRNAs is the miR - 200 family , members of which directly target ZEB1 and ZEB2 ( Fig . 2 B ) . During EMT these microRNAs are downregu - lated , resulting in an increase in ZEB1 and ZEB2 , thus pro - moting initiation of the mesenchymal transition ( 117 , 227 , 266 ) . In contrast , the EMT - promoting miR - 9 binds and inhibits the E - cadherin encoding mRNA and has been shown to induce EMT when overexpressed ( 181 ) . Additional epigenetic events associated with EMT include reduction of the heterochromatin marker H3K9Me2 , coupled with marked increase of the eu - chromatin marker H3K4Me , at least partially driven by changes in lysine - speciﬁc demethylase - 1 ( Lsd1 ) expression ( 189 ) . These epigenetic changes , recently reviewed ( 293 ) , emphasize the complex nature of EMT and also highlight the importance of acquiring and analyzing large datasets to begin to understand this process . Currently , tumor - node - metastasis ( TNM ) staging , a critical clinical tool ( 186 ) , is not capable of capturing the complexity of cancer in its entirety , as suggested by the heterogeneous survival patters of patients with identical TNM staging pat - terns . Thus far , the prognostic potential of EMT markers in lung cancer is limited , and large prospective studies are needed to evaluate and validate the precise clinical value of the EMT markers and signatures mentioned throughout this review . Precision targeting of different cancer cell subpopulations based on EMT status ( Fig . 2 ) is a critical endeavor , and at least four potential opportunities for targeted intervention have been identiﬁed : the microenvironment , EMT - associated signaling transduction cascades , mesenchymal cells , and blocking MET at secondary sites ( 21 , 71 ) . A prerequisite for the therapeutic targeting of EMT is precise detection and understanding of the process . Work by Yu et al . ( 344 ) provides a promising model for future clinical studies of EMT . Yu et al . analyzed changes in the epithelial and mesenchymal composition of patient circu - lating breast tumor cells ( CTCs ) . Interestingly , posttreatment analysis showed that patients with progressive disease while on therapy had an increased number of mesenchymal - like circu - lation cells compared with patients who responded to therapy ( 344 ) . Furthermore , mesenchymal - like CTCs had strong TGF - (cid:2) - induced expression signatures , suggested by the authors to be mediated by TGF - (cid:2) released from platelets ( 160 , 344 ) . No such study has been completed for lung cancer ; however , it has been shown that an EMT - associated secretory phenotype sig - nature that includes TGF - (cid:2) does have prognostic value in cases of lung cancer ( 249 ) . The EMT - associated signature strongly correlated with lymph node metastasis as well as tumor stage and grade . Importantly , the signature also predicted survival ( 249 ) . E - cadherin ( discussed below ) is another relevant EMT marker that has been shown to be of signiﬁcance in patients with lung cancer . Expression of E - cadherin has been shown to be associated with favorable outcomes in terms of overall survival in patients with small cell lung cancer ( 51 ) , and a meta - analysis of 13 studies found that in NSCLC E - cadherin downregulation had an unfavorable impact on survival ( 332 ) . It is clear that existing biomarkers must be further validated and additional biomarkers must be identiﬁed . The next section describes in detail how bioinformatics has been used to aug - ment the study of EMT in lung cancer . Many of the described resources present critical tools in the effort to study and understand EMT . APPLIED BIOINFORMATICS TO ANALYZE EMT IN NSCLC In the remainder of this review , we describe the use of orthogonal bioinformatics - based datasets to integrate transcrip - tome , proteome , and phosphoproteome data . Data integration is used to enrich the understanding of the signaling pathways on which EMT depends and to adequately study this inherently dynamic process ( 13 , 64 , 180 , 214 ) . Figure 1 in conjunction with Table 1 provides a general workﬂow and introduces resources useful for the investigation of EMT in lung cancer . As an example of the utility of bioinformatic approaches to extend understanding of EMT , we will focus part of the discussion on a small subset of EMT markers that have been shown to be of relevance in lung cancer ( 118 , 124 , 188 , 222 , 317 , 318 ) . These include TGF - (cid:2) ( TGFB1 – 3 ) ( 188 ) , NEDD9 / HEF1 ( 87 , 164 , 217 , 303 ) , E - cadherin ( CDH1 ) ( 43 , 46 , 298 , 318 , 334 ) , and (cid:2) - catenin ( CTNNB1 ) ( 299 ) ( Fig . 2 ) . In brief introduction to the group : TGF - (cid:2) . The TGF - (cid:2) ligands ( 55 ) regulate pulmonary mor - phogenesis , wound healing and normal lung homeostasis ( 19 , 188 ) . TGF - (cid:2) is commonly secreted both by cancer cells as well as tumor stromal cells ( 88 , 187 , 209 , 230 , 278 ) . Thus , TGF - (cid:2) can play a role in paracrine regulation when it is secreted from stromal cells ( 281 ) or via autocrine regulation ( 134 , 292 ) . In the case of paracrine signaling , the heterogeneity of cells within a tumor ( 106 , 176 , 192 ) and the regulatory diversity of TGF - (cid:2) [ acts as both , a tumor growth suppressant or promoter ( 188 , 232 ) ] are factors that can complicate accurate assessment of the phenotypic effects of TGF - (cid:2) on the tumor . Systematic analysis of single cells from stroma and tumors may be necessary to fully appreciate the connections between the two in terms of TGF - (cid:2) - induced activities ( 274 ) . TGF - (cid:2) exclusively binds to a hetero - tetrameric transmem - brane receptor composed of two type I receptors ( TGFBR1 , also known as ALK5 and T (cid:2) RI ) and two type II receptors ( TGFBR2 ) and regulates multiple signaling cascades , with the dominant cascade involving SMAD2 , SMAD3 and SMAD4 [ Fig . 2 B ; ( 277 ) ] . In normal lung cells and during the early stages of tumorigenesis , TGF - (cid:2) suppresses cell proliferation ; paradoxically , in late - stage tumor cells , TGF - (cid:2) stimulates proliferation , EMT , and invasion ( 187 , 254 ) . Levels of TGF - (cid:2) expression in NSCLC tumor cells correlate with disease stage ( 121 ) . Elevated TGF - (cid:2) detected in the plasma of patients with lung cancer prior to radiotherapy ( 18 , 156 , 157 ) , secreted from tumor and stromal cells , correlates with prognosis and also indicates course of disease posttherapy ( 156 ) . Exposure to exogenous TGF - (cid:2) can induce EMT in lung cells cultured in vitro ( 2 , 233 , 306 ) . NEDD9 . NEDD9 is a noncatalytic scaffolding protein asso - ciated with integrin - centered focal complexes , important for cell migration and prometastatic behavior in several types of solid tumors , including those of lung ( 49 , 86 , 139 , 217 , 286 ) . NEDD9 expression in tumors also correlates positively with a poorer overall survival ( 196 ) . NEDD9 expression is regulated in part by TGF - (cid:2) signaling , and NEDD9 mediates some TGF - (cid:2) - induced EMT migratory phenotypes via regulation of effectors including SRC , FAK , and DOCK3 / WAVE2 ( 3 , 22 , Review 704 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m 109 , 164 , 222 , 259 , 304 ) . In addition , NEDD9 interacts phys - ically with TGF - (cid:2) signaling effectors such as SMAD3 , SMAD6 , and SMAD7 , modulating their output [ Fig . 2 B ; ( 136 , 177 ) ] . Furthermore , NEDD9 regulates stability and trafﬁcking of E - cadherin ( 303 , 305 ) . In lung cancer , overexpression of TGF - (cid:2) or NEDD9 has been associated with a decrease in expression of E - cadherin and (cid:2) - catenin and an increase in N - cadherin ( 196 ) . NEDD9 associates with and is phosphory - lated by multiple SRC family kinases ( 10 , 185 , 304 ) . SRC is a potential therapeutic target in lung cancer ( 108 ) , and it has been shown that mammary tumors lacking NEDD9 have al - tered sensitivity to SRC inhibitors ( 287 ) . E - cadherin . E - cadherin is a member of the cadherin super - family ( 219 , 279 , 318 ) and is classiﬁed as a calcium - dependent cell - cell adhesion molecule ( 235 , 319 ) . For most epithelial tissue , E - cadherin is crucial for the maintenance of structural and functional integrity ; moreover , alterations , genetically or epigenetically driven , frequently result in tissue disorder . This can lead to increased tumor invasion and increased metastatic occurrence ( 226 ) . (cid:2) - Catenin is a direct binding partner of E - cadherin ( Fig . 2 B ) and is critical for proper adhesion ( 225 , 317 ) . In addition to its role in adhesion , (cid:2) - catenin is also a signaling transducer , particularly relevant to Wnt signaling ( 253 , 317 ) . E - cadherin loss frequently induces (cid:2) - catenin re - lease from adhesion complexes , freeing it for downstream signaling ; conversely high E - cadherin expression can limit (cid:2) - catenin signaling ( 124 ) . (cid:2) - Catenin - dependent signaling can also be limited by the Axin and APC destruction complex and marked for proteosomal degradation . However , active Wnt signaling disrupts the destruction complex , causing accumula - tion of (cid:2) - catenin in the cytoplasm , followed by translocation to the nucleus and interaction with TCF / LEF to induce transcrip - tion of target genes relevant to EMT ( 143 , 317 ) . Additional roles of (cid:2) - catenin , particularly those relevant to development , are reviewed in detail elsewhere ( 124 , 182 , 317 ) . The loss of E - cadherin and reduced (cid:2) - catenin expression have been linked to cancer resistance to therapy ( 40 , 250 , 296 ) and poor prognosis for patients ( 149 , 204 ) . Changes in expres - sion or function of E - cadherin and (cid:2) - catenin are highly corre - lated to EMT in lung cancer ( 149 ) . Kase et al . ( 149 ) found that reduced E - cadherin expression signiﬁcantly correlated with increased lymph node metastases in patients with NSCLC and that reduced (cid:2) - catenin signiﬁcantly correlated with poor prog - nosis . Although E - cadherin is generally accepted as a marker of epithelial cells ( 143 , 318 ) , it is important to be aware of the diverse nature of cell - to - cell adhesion of epithelial cells , which is dependent on cell type and context . For example , in some cases invasive cells actually retain E - cadherin expression ( 57 , 271 ) . Bioinformatic Support for Analysis of EMT - relevant Tumor Mutations Extensive effort has been devoted to the study of individual components of the EMT process ( 163 ) and has helped clarify the speciﬁc advantages that arise from larger scale studies that incorporate bioinformatics . Such advantages include the iden - tiﬁcation of biomarker sets of prognostic and therapeutic value ( 35 , 309 , 336 ) . These biomarkers also help to validate the appropriateness of models and increase the clinical translat - ability of experiments ( 64 ) . Furthermore , due to the transient nature of the EMT process ( 214 ) and the typical heterogeneity of tumors ( 23 , 69 , 106 , 165 , 176 ) , bioinformatics approaches can add statistical rigor to studies that would otherwise lack sufﬁcient power to reach compelling conclusions , particularly if data from multiple orthogonal approaches are integrated . The availability of large dataset of lung tumor - associated mutations can be used for these purposes ( 42a , 114 , 135 ) , so can samples from model organisms ( 46 ) and sets of different established cancer cell lines ( 1 , 16 , 100 ) . For example , data from Imielinski et al . reporting the genomic sequencing of 185 lung cancers ( 135 ) and TCGA data ( 42a ) are freely accessible through cBioPortal ( 47 , 99 ) and COSMIC ( 89 ) ( Table 1 ) . As of May 2014 , COSMIC contained information for 26 , 400 mutated samples for lung cancers and cBioPortal had a combined total of 1 , 872 lung tumor samples from eight individual datasets . COSMIC has the advantage of having a very intuitive platform layout that effortlessly navigates the user from mutations , to relevant studies on a speciﬁed gene , to tissue - speciﬁc mutation incidents , to type of mutation ( e . g . , deletion , insertion ) , and to drug sensitivity data in the context of a speciﬁc mutation . Compared with cBioportal , one downside of COSMIC is that only one term can be searched at a time , and COSMIC only provides information on somatic mutations . cBioportal allows convenient visualization and analysis of large - scale cancer genomics , transcriptomics , and proteomics data ( 47 ) . cBiopor - tal also allows input of multiple genes and then provides extensive data on co - occurrence of gene alterations , patient survival correlated to alterations of the input gene set , and related changes of 43 phosphoproteins and 117 proteins . Fur - thermore , in addition to genomics and proteomics information , cBioportal also provides RNA expression levels for some of the searchable datasets . For any gene of interest , it is now possible to quickly generate an idea of the frequency at which this gene is affected by mutations in tumors and the functional nature of the muta - tions . Figure 3 shows the workﬂow to accompany the follow - ing example . Typing “Imielinski” into the COSMIC query box rapidly retrieves the 75 , 708 mutations detected in 185 samples ( 16 , 563 genes analyzed per sample ) sequences for the study ( 135 ) . Searching within this extensive list by using the gene symbol for E - cadherin , CDH1 , identiﬁes ﬁve unique E - cad - herin mutations . The speciﬁc type of mutation is listed , and each gene is hyperlinked to a page with more information , such as drug sensitivity data for a given mutation , number of samples with a given mutation in the entire COSMIC database ( i . e . , for all tumor types ) , sequence and fusion information , and a list of all the studies that identiﬁed mutations in a given gene ( 89 ) . Clicking on a mutant - speciﬁc hyperlink reveals affected signaling pathways , which can be extremely useful in terms of hypothesis generation . In the case of E - cadherin , COSMIC identiﬁed six affected pathways : apoptosis , cell junction orga - nization , integrin cell surface interaction , signaling in immune system , cell cycle , and Wnt signaling . Further exploration of the EMT - relevant term “cell junction organization , ” through a hyperlink to the Reactome webpage ( platform for signaling pathway browser ; Table 1 ) , provides extensive data on path - ways and can also be used to explore the normal expression levels of E - cadherin and related proteins in normal lung tissue ( Fig . 4 A ) . These data indicate that in addition to E - cadherin , two cadherin family members ( CDH5 and CDH11 ) are strongly ex - pressed in lung tissue , as are two catenins ( CTNNA1 and Review 705 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m CTNND1 ) in addition to (cid:2) - catenin ( CTNNB1 ) . This suggests expansion of the query set to evaluate relevance of these proteins to lung cancer pathology and EMT . Now using the set of highly expressed cadherin : catenin complex proteins found in normal lung tissue ( CDH1 , CDH5 , CDH11 , CTNNB1 , CTNNA1 and CTNND1 ) to query cBio - Portal highlights that in nearly 50 % of lung cancer cases at least one of these genes is mutated , ampliﬁed , or deleted or has signiﬁcantly altered expression ( Fig . 4 B ) . Next , it is possible to look at clinical annotations for each sample , which in this case indicating that seven out of eight samples from patients with conﬁrmed , evaluated metastatic disease had alterations in the input proteins . Interestingly , the majority of alterations were transcriptional upregulation , and one striking feature high - lighted by this analysis was that none of the six samples had multiple genes altered simultaneously . This suggests the test - able hypothesis that an alteration in a single member of this group of cadherin : catenin proteins is sufﬁcient to support changes associated with metastatic disease ( Fig . 4 B ) . The provided example highlights how bioinformatics can be used to go from genomics screening data , to interaction networks , to clinically annotated data . This example also emphasizes the value of querying databases with sets of functionally interact - ing or paralogous genes . It is becoming increasingly clear that mutations and expression - level alterations affecting an impor - tant cancer process are often dispersed among members of a pathway regulating that process , rather than invariably clus - tered on a single pathway member ( 324 ) . Knowledge of which pathway members are mutated can inform decisions about how to therapeutically target the pathway . A particular strength of cBioPortal is the convenient testing of hypotheses regarding co - occurrence : i . e . , to investigate if gene alterations of interest are more likely to occur in a speciﬁc context . For example , Ding et al . ( 74 ) identiﬁed that the EGFR pathway is the most altered pathway in lung adenocarcinoma ( 50 / 188 specimens ) . Imielinski et al . ( 135 ) further reported frequent exonic alterations within EGFR and paralogous ki - nases ( 31 / 183 lung adenocarcinoma tumors ) . Using cBioPortal to identify mutual exclusion and co - occurrence of gene alter - ations reveals that EGFR and E - cadherin had a signiﬁcant co - occurrence ( Fig . 5 A ) . Interestingly , Yoo et al . ( 343 ) have reported that alterations of E - cadherin / (cid:2) - catenin predicts poor response to EGFR inhibitors in EGFR - mutation - positive pa - tients treated for lung cancer , noting that EMT is the potential resistance inducer . In this case , biological observations support the potential association between EGFR , E - cadherin , EMT , and therapy resistance ; however , this is not always the case and care must be taken to avoid erroneous conclusions . Bioinformatic Support for Analysis of EMT - relevant Changes in Gene Expression Gene expression patterns have been used to distinguish known types and subtypes of cancer ( 76 , 111 , 122 ) , and cancer - proﬁling studies have been able to identiﬁed or reas - signed molecular subtypes of cancer ( 61a , 289 ) . Using gene expression patterns to understand cancer - related processes on the molecular level is being explored . For example , Creighton et al . ( 64 ) developed proﬁles of EMT - associated genes that appeared coordinately across lung tumor specimens collected in TCGA ( 42a , 130 ) and a compendium of 11 additional lung adenocarcinoma datasets ( representing a total of 1 , 492 speci - mens ) . The complete set was normalized , clustered , and visu - alized with some of the resources discussed in detail below ( Table 1 ) . This approach identiﬁed a 16 - gene EMT signature [ including CDH1 , CDH2 , ﬁbronectin ( FN1 ) , matrix metallo - proteinases ( MMPs ) , VIM , and TWIST1 ; Fig . 2 ] for use in classifying tumor samples as mesenchymal - like versus epithe - lial - like ( 64 ) . The 16 - gene EMT signature requires further validation across a larger , independent set of patient samples , A B C D Fig . 3 . Workﬂow for mining gene - speciﬁc information . A : COSMIC [ green box ; ( 89 ) ] was used as the starting point for basic data - mining . Purple boxes correspond to the workﬂow described within the text . Gray boxes refer to separate examples also described within the text . Teal boxes highlight infor - mation retrievable with COSMIC . In addition to COSMIC , Reactome ( 65 ) ( B ) , String ( 91 ) and GeneMania ( 349 ) ( C ) , and cBioportal ( 47 , 99 ) ( D ) were used to for this speciﬁc workﬂow . See Table 1 for additional resources . Review 706 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m and it is clear that in order to ably capture the prognostic relevance of EMT markers additional steps must be taken . For example , ideally data concerning the microenvironment would be considered alongside each tumor sample , and systematic evaluation of whether the signature is found in large datasets would help ensure that all EMT drivers are identiﬁed ( 64 , 163 ) . The work by Creighton et al . also independently conﬁrmed an earlier study suggesting that low miR - 200 family expression levels in lung cancer correlates with expression of EMT mark - ers ( 110 , 117 , 228 ) , supporting the ability of high - throughput data mining - based studies to “compete” with gene - targeted low - throughput studies in reaching biological insights . It is easy to explore the cBioportal database using variations of the 16 gene EMT expression pattern identiﬁed by Creighton et al . ( 64 ) as representative of an EMT expression proﬁle for lung adenocarcinomas . Combining this search query with a search for NEDD9 , (cid:2) - catenin , E - cadherin , TGF - (cid:2) , and EGFR conﬁrms low E - cadherin typically correlates with high expres - sion of mesenchymal markers such as CDH2 , VIM , SNAIL , and FN1 ( Fig . 5 B ) . Additionally , co - occurrence of gene alter - ations ( mutations and expression ) were signiﬁcant for EGFR , TWIST1 , and CDH1 , suggesting increased EMT ; also altera - tions of the mesenchymal marker CDH2 signiﬁcantly co - occurred with TGFB1 , FN1 , and SNAI1 . Lastly , TGFB1 al - teration had a tendency to co - occur with alterations in the mesenchymal markers FN1 and VIM ( Fig . 5 A ) . NEDD9 was altered in 8 % of cases ; strikingly , the majority of alterations were mRNA upregulation and gene ampliﬁcation , supporting the role of NEDD9 as an oncoprotein ( 138 , 153 , 303 ) . For (cid:2) - catenin , 12 % of cases were altered . Here , the diverse alter - ations included no clear pattern of mutations , transcriptional up - and downregulation , and proteomic up - and downregula - tion , suggesting a more nuanced role ( Fig . 5 B ) . Despite the interesting EMT - related connections made pos - sible through the use of databases , a weakness in this approach was also highlighted : a relatively limited number of samples with E - cadherin downregulation are present in the datasets . This may be due to the fact that the biopsies processed to develop gene expression data are not necessarily taken from the periphery of a tumor or metastases , which is where EMT is more likely to be activated ( 80 , 310 , 320 , 329 ) . Hence , in the case of EMT , the capacity to perform facile and efﬁcient correlative analysis to support hypothesis testing is somewhat limited . The transient nature of EMT and its heterogeneous appearance present a major challenge ( 163 , 312 ) . The dearth of analyzed clinical samples from metastatic sites is likely to be A B Fig . 4 . Cadherins and catenins in normal and malignant lung tissue . A : visualized RNA - seq data for different cadherins and catenins from normal tissue samples ; the data were accessed through the Reactome platform , which in turn extracted it from the Expression Atlas [ Table 1 ; ( 148 , 231 ) ] . CDH1 ( epithelial cadherin ; E - cadherin ) , CDH11 ( osteoblast cadherin ; OB - cadherin ) , CDH5 ( vascular endothelial cadherin ; VE - cadherin ) , CTNNB1 ( (cid:2) - catenin ) , CTNNA1 ( (cid:4) - catenin ) , and CTNND1 ( catenin delta 1 ; also known as p120 and P120CAS ) are highly expressed in normal lung tissue . Color scale indicates mRNA expression levels , where greater color saturation represents higher expression levels compared with the other samples . Inserted box provides infor - mation regarding the lung samples used . B : cBioPortal was used to access and to visualize available data for 230 lung cancer tumor samples ( 99 ) . CDH1 , CDH11 , CDH5 , CTNNB1 , CTNNA1 , and CTNNB1 were used as the query terms . Each column repre - sents a single sample , with the top row pro - viding information regarding the metastatic status associated with each sample . The dashed box highlights the 8 samples associ - ated with veriﬁed distant metastasis ( M1 ) . Each square indicates proteomic , transcrip - tomic , or genomic alterations or no altera - tions ( gray square ) detected for the 6 query genes for each lung cancer sample . The per - centage after the gene name indicates the number of altered cases for the speciﬁc gene out of all 230 available cases . Compared with the original cBioPortal graphic , labels were slightly rearranged spatially and font sizes were increased for aesthetic reasons ; labels and deﬁnitions for MX , M0 , and M1 were added manually . RPPA , reverse phase protein array . Review 707 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m compensated for in the near future , as the database expands . At present , it can be partially compensated for by incorporating insights from studies using different mouse models addressing EMT ( 46 , 251 , 311 ) . Carretero et al . ( 46 ) used an extensive array of bioinformat - ics tools to better study EMT in specimens from a mouse model of lung cancer , supplemented with data from patient derived lung cancer samples . This study identiﬁed upregulation of EMT - associated genes in metastatic occurrence compared with primary tumors , including (cid:2) - catenin signature categories , NEDD9 - containing signature categories , as well as signatures containing the NEDD9 - interacting proteins SRC and FAK , TGFB1 , and CDH1 ( 22 , 217 ) . The resources used in this study included Gene Expression Proﬁle Analysis Suite [ GEPAS ; ( 295 ) ; recently merged with Babelomics ( 193 ) ] , GenePattern ( 63 , 248 ) , Genomica ( 25 , 268 ) , Gene Set Enrichment Analysis [ GSEA ; ( 199 , 290 ) ] , PhosphoPoint ( 339 ) , and NCBI Homolo - gene ( 210 ) . GEPAS / Babelomics . GEPAS / Babelomics is a web - based platform that allows the user to normalize , process , and analyze transcriptomics , proteomics , and genomics data and perform integrative analysis and functional proﬁling as well as data clustering and visualization . Data are easily uploaded , and many input sources are supported , such as the Affymetrix and Agilent platforms , lists of identiﬁers , lists of annotations , BLAST results , protein - protein interaction sources , and more ( 193 ) . Normalization can be accomplished by using biconduc - tor , log - transformation , imputation , and replica merging ( 104 , 193 ) . Furthermore , 80 cross - referenced identiﬁers for genes , proteins , signaling pathways , transcripts , array probes , and A B Fig . 5 . Co - occurrence of alterations in EMT markers in a set of lung cancer samples . A : presented are co - occurrence patterns of alterations in different genes relevant to EMT in lung cancer [ cBioPortal ; ( 47 , 99 ) ] . B : alteration patterns for the 16 - gene EMT signature determined by Creighton et al . ( 64 ) , in combination with NEDD9 , CTNNB1 , TGFB1 , and EGFR . The vertical row highlighted with dashed lines is a sample with CDH1 downregulation : different mesenchymal markers subsequently upregulated are highlighted with horizontal dashed lines . The black arrows on the left indicate up - or downregulation of mRNA expression levels . The % on the left indicates the number of samples out of 230 total samples that had alterations in the speciﬁed individual gene . Dashed lines and black arrows were added manually and are not generated by cBioPortal . Review 708 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m functional annotations are available ( 193 , 295 ) . These features make GEPAS / Babelomics well suited to normalize and cluster expression data from different sources ( e . g . , genotypically different samples , different tissue locations , different disease states , exposed to different pharmacological agents or different concentrations of the same pharmacological agents ) to identify gene clusters ( i . e . , gene signatures ) based on common expres - sion patterns ( 46 , 193 , 321 ) . NCBI Homologene and GenePattern . For example , Carret - ero et al . ( 46 ) used GEPAS to compare the differential gene expression levels and determine signiﬁcance of the changes between different mouse cohorts . Given that Carretero et al . used a mouse model to identify genes , it was necessary to use NCBI Homologene , a system designed to allow the query of genes in the context of cross - species homologies [ data from 21 completely sequenced eukaryotic genomes are accessible ( 210 ) ] to compare acquired data to human cases . Subsequently , GenePattern was employed ( 158 , 248 ) to visualize differently expressed genes . GenePattern is an extremely powerful plat - form that can perform over 100 different types of analyses . Besides options for interactive adjustment capabilities of visu - alized data output , supporting advanced gene expression anal - ysis ( 158 ) , GenePattern allows analysis of proteomic data ( 98 ) , single nucleotide polymorphism ( SNP ) analysis , and evalua - tion of ﬂow cytometry work . GenePattern provides access to the FLAME suite ( 244 ) for RNA - seq analysis , proﬁling DNA methylation patterns ( 338 ) , exome and whole - genome se - quence processing and analysis ( 165 ) , and more ( 248 ) . To facilitate the reproduction of experiments by other investiga - tors , GenePattern allows users to establish “analysis pipelines . ” In these , standardized sequences of analytical tools applied with consistent parameters to ensure reproducibility ( 79 , 129 ) . Parameters to , for example , normalize data , apply selection thresholds , cluster data , split datasets , and ﬁlter output infor - mation , are generally selected based on the purpose of the analysis . This is done on a case by case basis ( 248 ) . Ideally , a saved analysis pipeline is made available alongside published output data and raw data , to allow researchers to reproduce work with precision . Genomica . As an alternative or correlate to GenePattern , Genomica ( 268 ) generates a gene expression map based on adjustable parameters , such as up - and downregulation values , false discovery rate ( 218 ) correction , and Bonferroni correction ( 218 , 328 ) , and can be used as another practical way of visualizing and characterizing expression data . Genomica is useful for comparing a dataset to predetermined enriched functional gene groups such as gene signatures . Loading two datasets can be done rapidly once this Java - based software has been downloaded . Genomica compares gene sets using hy - pergeometric distribution based statistical tests and enrichment ﬁlters ( e . g . , P value and minimum / maximum number of en - riched genes per set ) can be applied . The work by Carretero et al . ( 46 ) serves again as a good example . Carretero et al . mined published data on human EMT signatures and used Genomica to compare these signatures to their experimentally derived murine - based EMT data . Importantly , this analysis shows that the signature identiﬁed in the murine model correlated with shorter survival and shorter metastasis free survival in human clinical samples ( 46 ) . GSEA . GSEA , a program similar to Genomica and another alternative for the analysis of gene expression data , is used to compare datasets from samples of different biological states , also with particularly focus on grouping genes ( i . e . , networks or signatures ) that have common biological functions , chromo - somal locations , and / or regulation . Comparing sets of genes using GSEA , Subramanian et al . ( 290 ) identiﬁed common biological pathways between two independent studies of lung cancer patients , for which single - gene analysis provided very limited information . GEO2R . An important concern when relying on databases is whether data collected on different platforms can be legiti - mately integrated or whether platform - speciﬁc artifacts pre - clude pooling . Addressing this concern , Byers et al . ( 40 ) proﬁled a group of lung cancer cell lines using multiple microarray platforms to establish a gene signature valid across different acquisition platforms ( Affymetrix U133A , U133B , Plus2 . 0 arrays , Illumina WGv2 , and Illumina WGv3 ) . Corre - lation values for the different microarray probes were calcu - lated to identify the most reliable probes . Next , GEO2R was used to compare the different expression datasets . The crux of GEO2R is its ability to effectively and rapidly identify differ - entially expressed genes across multiple samples ( 17 ) . It is important for any investigator using GEO2R to realize that this platform accesses and pulls data from the Gene Expression Omnibus database , a public repository , without consideration for experiment type and normalization process . It is up to the investigator to ensure that sample data accessed are indeed comparable . In careful use of this approach , Byers et al . ( 40 ) identiﬁed a novel EMT - associated EGFR - resistance mecha - nism involving the receptor tyrosine kinase Axl and its ligand GAS6 and developed a 76 - gene EMT signature based on gene expression proﬁles that can be identiﬁed using different acqui - sition platforms . The work by Byers et al . is promising and clinically relevant . Nevertheless , several potential weaknesses are evident . First , the approach used to determine the 76 genes excluded N - cadherin ( CDH2 ) because it did not meet the established criteria . N - cadherin is a commonly cited mesen - chymal marker that was selected by Byers et al . ( 40 ) to deﬁne the mesenchymal category , yet it still failed to meet the criteria necessary to be included in the signature . Second , the 76 genes were selected based on 54 NSCLC cell lines , an approach that fails to appreciate the input of the microenvironment . This may explain why Byers et al . did not ﬁnd the EMT signature to have any prognostic value in terms of disease control or progression - free survival . Independent validation of the 76 - gene signature across a larger sample set ( Byers et al . evaluated only 139 samples ) would help establish the potential of this signature ( 163 ) . Bioinformatic Support for Analysis of EMT - relevant Protein Signatures A current frontier of analysis of cancer biology is in the area of proteomics . The issues discussed above limiting the effec - tiveness of gene expression databases informing EMT , notably , biopsies with limited representation of specimens from tumor margins or metastases , and the transient nature of the EMT process , at present also apply to protein - based data . Neverthe - less , some work is beginning to suggest approaches that can be further developed , as technologies and databases improve . For example , Carretero et al . ( 46 ) identiﬁed hyperphosphorylation of a group of established SRC substrates as a signature present Review 709 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m in primary lung tumors and metastases , compatible with the upregulation of NEDD9 and its partner SRC in tumors that are undergoing EMT . First , phosphoproteins were isolated from murine tumors as well as human cancer cells using immobi - lized antibodies , followed by liquid chromatography - tandem mass spectrometry analysis to establish phosphorylation pro - ﬁles . To ﬁnd putative upstream kinases for the identiﬁed phosphoproteins , four independent databases were used to maximally capture information on kinase target site speciﬁcity : PhosphoELM ( 75 ) , HPRD ( 151 ) , Swissprot / UniProt ( 8 ) , and NetworkKIN [ Table 1 ; ( 46 , 173 ) ] . Based on the hyperphosphorylation data as well as identiﬁed gene expression patterns , Carretero et al . ( 46 ) hypothesized that the triple combination of dasatinib ( Src inhibitor ) , AZD2644 ( MEK1 / 2 inhibitor ) , and BEZ135 ( PI3K - mTOR inhibitor ) would be a viable treatment approach . The triple combination caused signiﬁcant tumor regression in vivo and was superior to dasatinib alone or dual drug combinations . As SRC inhibitors speciﬁcally , and targeted inhibitors in general , tend to be most successful as part of combination therapies , this class of approach has obvious value ( 38 , 154 , 242 , 247 ) . An alternative approach for the assessment of proteomic change is the use of reverse - phase protein arrays [ RPPA ; ( 302 ) ] . RPPAs use antibody panels to query over 100 cancer - relevant proteins for expression or activity ( as reﬂected by antibody - detectable phosphorylation sites ) . Byers et al . ( 40 ) integrated RPPA - derived proteomic data for epithelial and mesenchymal cells by hierarchical clustering , also incorporat - ing , for comparative measures , analysis of different microarray platforms to analyze EMT signatures ( discussed above ) . The proteomic analysis showed that E - cadherin was the most sig - niﬁcantly different protein between the epithelial ( highly ex - pressed E - cadherin ) and the mesenchymal group ( low expres - sion of E - cadherin ) . Importantly , E - cadherin mRNA expres - sion levels varied signiﬁcantly for the different E - cadherin probes , in terms of correlation to the protein levels , highlight - ing the need to consider a signature of genes rather than a single gene , due to acquisition associated variation , for tran - scriptional analyses and preferably integrating proteomic data . Byers et al . ( 40 ) then tested several drugs on mesenchymal and epithelial cell lines , categorized according to their data analy - sis , to establish sensitivity and resistance patterns . Cell lines classiﬁed as more mesenchymal in characteristics were more resistant to EGFR and PI3K / Akt inhibitors , conﬁrming the validity of the informatics predictors . Importantly , bioinfor - matics enabled application of the same analysis pipeline used for cell lines analysis to analyze lung cancer tissue samples from patients , and the experimentally determined EMT signa - ture was concluded to potentially serve as a marker of erlotinib activity in some patients ( 40 ) . This example thus simultane - ously emphasizes the value of informatics approaches in sug - gesting clinically useful predictors but at present also indicates the need to use multiple probe sets to evaluate gene expression data as well as proteomics data to identify predictive patterns . Building Simple Local Relational Networks for Proteins of Interest There are other ways web - based tools can quickly and conveniently support studies of genes nominated as of interest for EMT in lung cancer ( or any other purpose ) . For example , we used cBioPortal ( 47 , 99 ) and two additional platforms [ STRING ( 91 ) and GeneMania ( 349 ) ] to investigate proteins and genes functionally and physically interacting with NEDD9 , with emphasis on SRC ( Fig . 3 ) . All three programs are web - based , free , and fairly intuitive to use on a basic level . Figure 6 A highlights one of the available cBioPortal features . Shown is the analysis of human lung adenocarcinoma datasets that examines different protein expression levels of SRC and phosphorylated SRC using SRC and NEDD9 as the query input . This was done to test the hypothesis that the expression of these proteins was coordinately regulated . The analysis showed that genomic or transcriptional alterations ( predomi - nantly ampliﬁcation and mRNA upregulation ) of NEDD9 in lung cancer correlates with increased levels of p - SRC ( pY527 ) , the most signiﬁcantly changed protein out of 47 tested phos - phoproteins , and total levels of SRC ( P (cid:5) 0 . 000212 and P (cid:5) 0 . 019 respectively ; Fig . 6 A ) , supporting one potential mecha - nism by which NEDD9 contributes to EMT . cBioPortal pro - vides an extensive list of altered protein expression levels , with associated P values ; additionally , data on mutations , coexpres - sion , survival data and more , for genes of interest are also provided . Next , we used STRING ( 91 ) and GeneMania ( 349 ) to investigate how SRC and NEDD9 relate to each other in the context of a protein interaction networks ( Fig . 6 , B and C ) . STRING and GeneMania access multiple databases reporting protein - protein interactions and generate simple networks around query proteins within seconds . Networks centered on NEDD9 and SRC show close links between the two proteins ( Fig . 6 , B and C ) and also indicate interactions to other proteins of relevance , providing links to the information used to con - struct the databases . Hence , this form of analysis can help support and organize literature searches . Notably , the networks generated by the two programs are not identical . For example , STRING ﬁnds evidence for a direct link between NEDD9 and SRC , whereas GeneMania does not . As always , the individual investigator must use judgment and conﬁrm suggested results in the literature or by experiment . Liu et al . ( 174 ) provide a detailed instructional guide to generating both simple and more complex interaction networks , and they provide extensive information regarding advanced functions of STRING and GeneMania , as well as information on many other available programs to extend this form of analysis . Current Limitations of Bioinformatics Because of the great investments being made in the gener - ation of high - throughput data and the increasing dependence of clinical management of cancer patients on genomic informa - tion ( see below ) , bioinformatics is inevitably assuming a greater role across many disciplines . Within the next decade , continued improvements in resources will help to organize the complexity of the EMT process . However , it is important to realize some of the limitations of bioinformatics ( Fig . 1 ) . First , the inconsistencies introduced by different acquisition plat - forms ( 40 ) as well as those introduced during the bioinformat - ics analysis itself ( 79 , 129 ) have been mentioned to some extent above . Working closely with committed bioinformati - cians and statisticians best minimizes both of these aspects . At the same time , bioinformatics can be used successfully to expose inconsistencies and to cross - compare data that theoret - Review 710 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m ically should correlate . For example , Haibe - Kains et al . ( 119a ) found that two large pharmacogenomic studies ( 16 , 100 ) pre - sented expression proﬁles in cell lines with remarkable corre - lation between the two studies . Unfortunately , the drug re - sponse data presented in the same two studies were highly discordant . The most likely explanation for the inconsistent drug response data is the use of slightly different assays and experimental protocols , unfortunately a common issue in high - throughput studies ( 24 ) . Similar problems encountered for gene expression data were at least partially addressed with the establishment of strict standards ( 207 ) , which would be desir - able for future pharmacogenomic efforts . Discordance can also be observed in the simple interaction network presented for NEDD9 ( Fig . 6 , B and C ) , emphasizing the selective nature of algorithms using different metrics to probe similar resources . Where possible , the approach taken by GenePattern ( noted above ; Table 1 ) in establishing standard analytical pipelines will help ensure reproducibility ( 248 ) . The problem of limited exchange among scientists in terms of computational analyses of published data remains and hinders standardization and consistency . Considering genes as groups rather than on an individual basis may be most appropriate , for example , by looking at signaling pathways and biological processes such as EMT as functional units ( 29 , 290 , 324 ) . Grouping individual data points may also help address another limitation of bioinformatics in terms of its clinical relevance : its propensity to overwhelm clinicians and patients ( 28 ) . One promising emergence prompted by the need for facilitated collaboration among scientists and institutions in terms of data sharing is SAGE / Synapse ( 96 ) . In very broad terms , the SAGE / Synapse platform can help scientists address several funda - mental hindrances , such as ﬁnding data , understanding work - ﬂow , analyzing data , and establishing viable and vibrant col - laborations ( Table 1 ) . It is critical that information is presented in a comprehensible manner , in a way that saves time and directs decision - making , instead of simply adding more items to a decision - making tree , items that may or may not be signiﬁcant . BIOINFORMATICS IN SUPPORT OF PRECISION ONCOLOGY Precision oncology integrates cancer genomics , metabolo - mics , proteomics , and transcriptomics technologies to inform the treatment strategies for individual patients ( 280 ) . The discovery of the Philadelphia chromosome , a translocation leading to a constitutively active BCR - ABL tyrosine kinase ﬁrst described in chronic myelogenous leukemia ( CML ) ( 220 ) , and the subsequent development of the ﬁrst compound for targeted cancer therapy , imatinib ( 78 ) , which binds to and inhibits the activated BCR - ABL oncogene , can be considered the ﬁrst major and quite revolutionary breakthrough of preci - sion oncology . This treatment approach has had a dramatic impact on patient survival in some cases ( 77 ) , and the success of imatinib initiated the progressive introduction of a new A B C Fig . 6 . Exploring changes in protein expression and building simple local protein - protein interaction ( PPI ) networks . A : expression levels of phospho - SRC and total SRC are shown in a comparison of samples with no alterations for NEDD9 and SRC ( Unaltered ) to samples with at least one alteration in NEDD9 or SRC ( Altered ) . RPPA data were accessed with cBioPortal ; RPPA score ( on y - axis ) refers to the z - score for each sample based on average protein abundance ( 47 , 99 ) . A signiﬁcant difference exists between the 2 categories ( Altered vs . Unaltered ) for both phospho - SRC and total SRC . STRING ( B ) and GeneMania ( C ) were used to build PPI networks to highlight the relationship between NEDD9 and SRC . For the network generated from STRING ( 91 ) , only data with medium or higher conﬁdence scores [ scores are computed by combining the probabilities for a given interaction based on evidence from different sources and correcting for the probability of random observations ( 325 ) ] obtained by limited methods ( coexpression , gene fusion , and experiments ) were included to generate the displayed interactions ( blue lines ) . Only physical interactions ( pink lines ) are shown for the PPI network generated with GeneMania ( 349 ) . Protein nodes were manually arranged for both PPI networks . Review 711 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m category of treatment , one not exclusively based on location and histology , but also considerate of speciﬁc mechanistic aspects driving pathological progression . To date , precision oncology has sought to identify mutations in driver oncogenes and to suggest ways to therapeutically target these drivers ( 324 ) . Failure to understand the feedback circuits between signaling pathways currently limits the effec - tiveness of targeting mutated drivers with matching drugs , contributing to the problem of unexplained de novo and ac - quired resistances ( 112 ) . As precision medicine is evolving , it has become evident that precision medicine requires precision data acquisition , precision data analysis , precision data inter - pretation , and , last but not least , precision communication between the medical team and the patients . Appropriate bioin - formatics helps address many of these requirements ( 96 , 101 , 280 , 291 ) . Given the linkages between EMT and drug resis - tance noted above , incorporation of datasets addressing this process will inevitably assume a larger role in therapeutic decision making in coming years . Matching Therapy to Patient : Targeting EMT At present , few therapeutic agents directly target proteins involved in EMT for either lung cancer or other cancers . Instead , driver oncogenes targeted in speciﬁc subsets of lung cancer patients include EGFR ( 135 , 198 ) or EML4 - ALK ( 159 , 276 ) . When matched to the appropriate patients , these have remarkable response rates . Not surprisingly , an ever increasing number of cancer - focused clinical trials require in - depth anal - ysis of patient biopsy samples to determine drug response markers ( 20 ) , a trend that is likely to continue . The key prerequisites for clinical translation of an individualized treat - ment approach into a successful early - phase trial still present a formidable challenge . First , reproducible and uniform charac - terization of the genomes of patients’ tumors by state - of - the - art technologies must be achieved ( using samples from multiple tumor sites ) . Second , the genomics data must be ﬁltered through a knowledge base of existing and emerging anticancer drugs to select the optimal treatment regimen . Third , an anno - tated list must be presented to the treating oncologist to inform clinical decisions ( 90 ) . However , multiple challenges must be addressed before this can be done . Tumor samples are substan - tially heterogeneous genetically , with a mixture of malignant and nonmalignant cells , as well as being composed of different clones and subclones within individual tumors ( 195 , 294 ) . Even though many of critical points remain to be addressed , it is encouraging that several clinical trials are already investi - gating the possibility of using molecular proﬁling to guide therapeutic interventions ( 152 , 168 , 313 , 314 ) . When considering targeting EMT in the context of precision medicine , there are additional issues . First , as noted above , the EMT program is not active in all tumor cells : it is most active at tumor margins and in metastasizing or recently metastasized cells . It is harder to identify the correct “target” population . Second , although some driver oncogenes and tumor types are signiﬁcantly associated with a higher incidence of EMT ( i . e . , melanoma is signiﬁcantly more metastatic than prostate can - cer ) , the EMT program itself is more likely to be dynamically regulated at the epigenetic level , again separating the phenom - enon from readily targetable upstream drivers . Third , one theoretical objection to using drugs to target EMT arises from the pragmatic handling of patients receiving initial diagnoses in the clinic . Before EMT has occurred , in situ tumors are excised surgically . Conversely , if tumors have already metastasized , common in lung cancer diagnosis , one could argue that it is too late : EMT has already occurred . Hence , this would limit the primary use of EMT - targeting agents to early invasive tumors , which constitute a small subset of the whole . An answer to these objections lies in consideration of the genes identiﬁed by bioinformatics as part of the EMT signature and the growing recognition that there is signiﬁcant overlap between features of cells that have undergone EMT with those in a drug - resistant “stem cell - like” compartment ( 184 , 237 , 285 ) . Targeting intermediate elements of EMT cascades ( Fig . 2 B ) , such as SRC ( 97 , 108 , 287 ) or RhoA ( 32 , 205 , 272 ) , may be broadly useful in reducing survival of cells treated with cytotoxic agents by removing them from stem cell - like differ - entiation states . Additionally , and again returning to clinical practice , many lung tumors are diagnosed in elderly or frail patients , for whom surgical resection of a primary tumor poses signiﬁcant risks or who cannot tolerate the side effects of chemo - or radiotherapy . In some of these patients , watchful waiting is advised ( 155 , 267 ) . If a well - tolerated EMT inhibitor were available for use during this period of watchful waiting , this might signiﬁcantly reduce the later appearance of metas - tases in this vulnerable patient group . Furthermore , considering that 90 % of human cancer deaths are due to metastases and much of the disease’s incurability is due to metastases ( 46 , 48 ) , inhibition of EMT to limit the deadliest aspect of cancer would have a tremendous impact . Based on bioinformatics approaches , what EMT proteins might make good targets ? The problem is not just identifying potential EMT - related proteins that may make good targets based on biological roles , but also the feasibility of targeting such proteins pharmacologically . Here , too , bioinformatics resources can provide data that assist in prioritizing targets and identifying small molecules that may interact with a given target . One of the most comprehensive resources available to investigate “drug - event” datasets is the Comparative Toxicog - enomics Database [ CTD ; ( 70 ) ] . CTD covers 23 , 200 , 343 toxi - cogenomic relationships , which includes 969 , 979 curated chemical - gene interactions and 1 , 618 , 527 chemical - disease as - sociations ( 190 , 935 of them are curated ) . Different categories can be used to narrow searches , such as Gene Ontology ( GO ) , chemicals , disease , gene , organism , pathways , or references . Selecting the GO category and using “EMT” as the input term provides a brief description of EMT and makes available a tab with established genes involved in EMT . CTNNB1 is one of the genes listed ; clicking on the accompanying hyperlink opens a site with the top 10 interacting chemicals , one of which is indomethacin , a nonsteroidal anti - inﬂammatory drug . CTD further provides the references for each indomethacin - CTNNB1 interaction , with a one - line summary statement of the ﬁndings for each reference . In this speciﬁc case , the references suggest that indomethacin may result in decreased CTNNB1 - associated pathogenesis . Thus , studying the impact of indomethacin in the context of EMT speciﬁcally could be of interest . A similar approach using “CDH1” as the search term indicates that aﬁmoxifene results in increased expression of CDH1 . Considering the interaction between CDH1 and CTNNB1 ( Fig . 2 B ) , it would be reasonable to hypothesize that combining indomethacin with aﬁmoxifene could limit EMT ; Review 712 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m however , clearly extensive biological studies would be neces - sary to further this idea ( Fig . 1 ) , but the general notion of how CTD can be used to think about novel drug combinations based on known biology should not be dismissed . Additional useful resources for gene - chemical interactions are listed by Path - guide , which provides a list of 547 ( as of May 2014 ) biological pathway and molecular interaction - related resources ( 12 ) . Predicting Therapeutic Resistance : a Role for EMT ? Unfortunately , at present almost all patients receiving tar - geted therapy experience relapse ( 161 ) . Study of relapse mech - anisms suggests some relevance to induction of EMT . For example , in EGFR - mutant lung cancer , ampliﬁcation of c - MET ( 83 , 316 ) , mutations in PIK3CA ( 269 ) , or mutations in BRAF ( 223 , 241 ) , which allow bypass activation of critical downstream signaling , provide resistance to EGFR - targeting drugs . c - MET activation is a particularly interesting resistance mechanism , as it not only induces EMT but also involves several of the aforementioned proteins to do so ( 107 ) . Xi et al . ( 333 ) showed that c - MET activation promotes increased phos - phorylation of the NEDD9 - associated protein SRC ( 3 , 287 ) , which reduces the interaction of (cid:2) - catenin with E - cadherin , and instead leads to (cid:2) - catenin phosphorylation , nuclear trans - location and EMT induction . Lung tumors have also been shown to form resistance by transforming to small - cell lung cancer , as well as EMT ( 52 , 269 ) . The molecular mechanisms of EMT - associated resistance to EGFR inhibitors , observed both in patients ( 269 ) and cell lines ( 62 , 92 ) , is not yet fully understood ; the broader EMT and EGFR - inhibitor - associated expression changes described above , obtained through bioin - formatics means , should contribute to understanding these processes ( 40 , 46 ) . Pharmacogenomics , noted brieﬂy above , is an emerging ﬁeld that attempts to understand how genomic information can be used to predict therapeutic responses to pharmacological agents ( 123 ) . Speciﬁc mutations and variations can serve as markers used to identify subpopulations that are either more or less likely to beneﬁt from certain therapeutic agents , succumb to adverse drug reactions , or require variations in drug dosing . Pharmacogenomic DNA markers , aside from identifying via - ble tumor targets , are also critical to fully appreciate drug absorption , distribution , metabolism , and elimination ( 191 , 330 ) . The best - known pharmacogenomics resource currently available is PharmGKB ( 300 , 331 ) , although other databases do exist ( 283 ) . PharmGKB covers clinical information ( e . g . , dosing guidelines , drug labels , clinical annotations , and asso - ciated publications ) and genotype - drug - response relationships . In the case of lung cancer , the most relevant gene covered by PharmGKB is EGFR , described here as an example of the potential use of this resource . Hodoglugil et al . ( 126 ) used PharmGKB to give a pharmacogenomics overview of EGFR in the treatment of NSCLC . First , the authors took advantage of the pathway descriptions provided by PharmGKB for different targets , which , in the case of EGFR , breaks down available pharmaceuticals into two categories : tyrosine kinase inhibitors [ bind the EGFR kinase domain intracellularly ( 175 ) ] and monoclonal antibodies [ block EGFR ligands from binding ; ( 175 ) ] . Next , PharmGKB was used to pull up a table of known pharmacogenomic EGFR variants . The authors then summa - rized the information on speciﬁc variant rs11568315 , the oc - currence of which is linked to a better clinical response to the tyrosine kinase inhibitor geﬁtinib ( 307 ) . The beneﬁt of quickly and effectively accessing pharmacogenomics data is clearly of immense value to both researchers and clinicians ; however , more data are needed as well as expansion to other genes linked to therapeutic resistance , such as those in EMT signal - ing cascades . Speciﬁc pharmacological inhibition of EMT poses plentiful challenges . One potential approach to blocking or reversing EMT is by increasing E - cadherin expression ( 178 ) , which could be achieved by inhibiting negative regulators of surface E - cadherin . For example , SRC inhibition signiﬁcantly in - creases E - cadherin in vitro , suggesting the use of SRC - inhib - itory agents such as dasatinib for this purpose in vivo ( 206 ) . However , it is unlikely that targeting a single protein will limit EMT in a clinical setting . Targeting multiple EMT relevant and E - cadherin - associated proteins simultaneously may be a more promising approach . For example , using the histone deactylase inhibitor vorinastat , which has been shown to prevent TGFB1 - induced decrease of E - cadherin ( 133 ) , in combination with an SRC inhibitor would be a hypothesis - driven , rational drug combination study focused on limiting EMT . An alternative approach to increase E - cadherin may be treatment with the proteasome inhibitor marizomib , a drug observed to increase E - cadherin and inhibit Snail , leading to decreased tumor inva - sion and migration ( 15 ) . Yet another potentially promising approach is targeting signaling proteins downstream of mem - brane - bound receptors , such as TGF - (cid:2) and EGFR , which induce EMT ( 115 , 179 ) . First preclinical studies have shown that inhibiting MEK or ERK1 / 2 does indeed induce epithelial markers and limit invasiveness ( 39 ) . Clearly , most of these proteins also have functions beyond a role in EMT : clinical gain may come from parallel inhibition of multiple processes that support malignancy . Finally , tumor heterogeneity is inherently linked to EMT ( 183 , 184 , 251 , 329 ) . Heterogeneity within individual tumors ( clonal and subclonal mutations ; microenvironment - speciﬁed epigenetic variation ) provides a potential explanation for both innate and acquired drug resistance . Targeted therapy against one driver mutation could select for the enrichment and clonal expansion of a small number of cells resistant to that agent ( 42 , 116 ) . An intriguing mathematical model ( 7 ) has recently been applied by Bozic et al . ( 38 ) to explore the possibility of anticipating cancer evolution and treatment failure based on patient - derived data . Upon application to a set of patients with varying tumor burden , the model suggested that monotherapy with a targeted therapeutic will result in resistance , whereas simultaneous dual therapy may provide long - term disease con - trol ; however , for patients with large disease burden , triple therapy was suggested . In this case , bioinformatics provides a framework for potential advantages of reconsidering the design of clinical trials for targeted therapies , and it provides expec - tations for targeted therapy in general ( Fig . 1 ) . Future efforts will also need to address the heterogeneous nature of tumor microenvironments in driving drug resistance and EMT . At present , few computational models take into account relevant biological factors , such as the abundance of growth factors derived from tumor - adjacent stroma ( Wnt , TGF - (cid:2) , FGF , EGF , and others ) and the local inﬂammatory environment ( 14 , 94 , 141 , 160 , 245 ) , even though these are highly relevant : ulti - Review 713 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m mately , bioinformatic models will need to factor in these important variables . CONCLUSION AND FUTURE DIRECTIONS Although transient , EMT is a critical aspect of cancer biology and over the past decade signiﬁcant headway has been made in terms of understanding this process . Much is still to be learned . From a therapeutic standpoint , as targeted drugs im - pose varying selective pressures , resistance emerges through dynamic events affecting proteins integral to the EMT program and other signaling pathways ( 81 ) . Adding inter - and intratu - mor as well as interpatient heterogeneity ( 23 , 69 , 106 ) into the mix , and it becomes clear that in the absence of a systems - level understanding , the individual oncologist will not typically be able to therapeutically exploit data from ever more detailed molecular characterization of tumors . While basic investiga - tions remain necessary to understand the core biological pro - cesses of EMT and metastasis , current efforts to establish comprehensive , interoperable , and easily accessible databases are necessary to drive progress ( Fig . 1 ) . In the past , there have been calls to make training in basic computational and infor - matic approaches a component of graduate education in biol - ogy and medical school : the need has never been more appar - ent . Precision oncology is the future of cancer treatment , with many clinical trials already investigating the feasibility and impact of this approach ( 152 , 168 , 313 , 314 ) . The promise is tremendous , but the challenges remain signiﬁcant . Considering that targeted therapy still beneﬁts only 10 – 20 % of patients for only 6 – 12 mo ( 128 ) , the road ahead will not be easy . It is also clear that monotargeted therapy fails rapidly and even dual - targeted therapy is unlikely to provide long - term relief or even be curative ( 38 ) . Though speculative , we think that solutions are on the horizon . The challenge of target identiﬁcation and disease evolution as well as disease heterogeneity may be addressed via serial liquid biopsies and analysis of circulating tumor cells and circulating tumor DNA ( 4 , 31 , 33 , 72 , 73 , 344 ) . In combination with the advent of single cell sequencing ( 82 , 208 , 240 ) , this approach should make it possible to accurately deﬁne and track an individual’s pathology . Improved intravital microscopy will allow better investigation of dynamic cancer - related processes such as EMT and will help ﬁll in some of the missing links ( 163 , 234 , 262 ) . The expansion of current data - bases will provide the necessary reference resource to help predict the behavior of an individual’s disease . For these efforts to yield fruit , standardization of data acquisition pro - cesses , data normalization and analysis procedures and globe - wide access to the data are essential . Finally , new drug devel - opment should beneﬁt from the wealth of data , and systems such as personalized “organs on a chip” ( 131 , 132 ) may ultimately provide the tools needed by the industry to truly personalize oncology . GRANTS The authors were supported by National Cancer Institute Grants U54 CA - 149147 , R21 CA - 181287 , R01 CA - 63366 , and P50 CA - 083638 ( to E . A . Golemis ) , F30 CA - 180607 ( to T . N . Beck ) and Core Grant CA - 06927 ( to Fox Chase Cancer Center ) . DISCLOSURES No conﬂicts of interest , ﬁnancial or otherwise , are declared by the author ( s ) . AUTHOR CONTRIBUTIONS Author contributions : T . N . B . and A . J . C . prepared ﬁgures ; T . N . B . , A . J . C . , N . R . S . , and E . A . G . drafted manuscript ; T . N . B . , N . R . S . , and E . A . G . edited and revised manuscript ; T . N . B . , A . J . C . , N . R . S . , and E . A . G . approved ﬁnal version of manuscript . REFERENCES 1 . Abaan OD , Polley EC , Davis SR , Zhu YJ , Bilke S , Walker RL , Pineda M , Gindin Y , Jiang Y , Reinhold WC , Holbeck SL , Simon RM , Doroshow JH , Pommier Y , Meltzer PS . The exomes of the NCI - 60 panel : a genomic resource for cancer biology and systems pharmacology . Cancer Res 73 : 4372 – 4382 , 2013 . 2 . Abulaiti A , Shintani Y , Funaki S , Nakagiri T , Inoue M , Sawabata N , Minami M , Okumura M . Interaction between non - small - cell lung cancer cells and ﬁbroblasts via enhancement of TGF - beta signaling by IL - 6 . Lung Cancer 82 : 204 – 213 , 2013 . 3 . Ahn J , Sanz - Moreno V , Marshall CJ . The metastasis gene NEDD9 product acts through integrin beta 3 and Src to promote mesenchymal motility and inhibit amoeboid motility . J Cell Sci 125 : 1814 – 1826 , 2012 . 4 . Alix - Panabieres C , Schwarzenbach H , Pantel K . Circulating tumor cells and circulating tumor DNA . Ann Rev Med 63 : 199 – 215 , 2012 . 4a . American Cancer Society . Cancer Facts & Figures 2014 . http : / / www . cancer . org / research / cancerfactsstatistics / cancerfactsﬁgures2014 / index [ 03 . 09 . 14 ] . 5 . Amirian ES , Bondy ML , Mo QX , Bainbridge MN , Scheurer ME . Presence of viral DNA in whole - genome sequencing of brain tumor tissues from the cancer genome atlas . J Virol 88 : 774 – 774 , 2014 . 6 . Ansieau S , Bastid J , Doreau A , Morel AP , Bouchet BP , Thomas C , Fauvet F , Puisieux I , Doglioni C , Piccinin S , Maestro R , Voeltzel T , Selmi A , Valsesia - Wittmann S , de Fromentel CC , Puisieux A . Induc - tion of EMT by twist proteins as a collateral effect of tumor - promoting inactivation of premature senescence . Cancer Cell 14 : 79 – 89 , 2008 . 7 . Antal T , Krapivsky PL . Exact solution of a two - type branching process : models of tumor progression . J Stat Mechan Theory Exp 2011 : 2011 . 8 . Apweiler R , Bateman A , Martin MJ , O’Donovan C , Magrane M , Alam - Faruque Y , Alpi E , Antunes R , Arganiska J , Casanova EB , Bely B , Bingley M , Bonilla C , Britto R , Bursteinas B , Chan WM , Chavali G , Cibrian - Uhalte E , Da Silva A , De Giorgi M , Fazzini F , Gane P , Castro LG , Garmiri P , Hatton - Ellis E , Hieta R , Huntley R , Legge D , Liu WD , Luo J , MacDougall A , Mutowo P , Nightingale A , Orchard S , Pichler K , Poggioli D , Pundir S , Pureza L , Qi GY , Rosanoff S , Sawford T , Shypitsyna A , Turner E , Volynkin V , Wardell T , Watkins X , Zellner H , Corbett M , Donnelly M , Van Rensburg P , Goujon M , McWilliam H , Lopez R , Xenarios I , Bou - gueleret L , Bridge A , Poux S , Redaschi N , Aimo L , Auchincloss A , Axelsen K , Bansal P , Baratin D , Binz PA , Blatter MC , Boeckmann B , Bolleman J , Boutet E , Breuza L , Casal - Casas C , de Castro E , Cerutti L , Coudert E , Cuche B , Doche M , Dornevil D , Duvaud S , Estreicher A , Famiglietti L , Feuermann M , Gasteiger E , Gehant S , Gerritsen V , Gos A , Gruaz - Gumowski N , Hinz U , Hulo C , James J , Jungo F , Keller G , Lara V , Lemercier P , Lew J , Lieberherr D , Lombardot T , Martin X , Masson P , Morgat A , Neto T , Paesano S , Pedruzzi I , Pilbout S , Pozzato M , Pruess M , Rivoire C , Roechert B , Schneider M , Sigrist C , Sonesson K , Staehli S , Stutz A , Sundaram S , Tognolli M , Verbregue L , Veuthey AL , Wu CH , Arighi CN , Arminski L , Chen CM , Chen YX , Garavelli JS , Huang HZ , Laiho K , McGarvey P , Natale DA , Suzek BE , Vinayaka CR , Wang QH , Wang YQ , Yeh LS , Yerramalla MS , Zhang J , Consortium U . Activities at the Uni - versal Protein Resource ( UniProt ) . Nucleic Acids Res 42 : D191 – D198 , 2014 . 9 . Armstrong AJ , Marengo MS , Oltean S , Kemeny G , Bitting RL , Turnbull JD , Herold CI , Marcom PK , George DJ , Garcia - Blanco MA . Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers . Mol Cancer Res 9 : 997 – 1007 , 2011 . 10 . Astier A , Manie SN , Avraham H , Hirai H , Law SF , Zhang Y , Golemis EA , Fu Y , Druker BJ , Haghayeghi N , Freedman AS , Avra - ham S . The related adhesion focal tyrosine kinase differentially phos - phorylates p130Cas and the Cas - like protein , p105HEF1 . J Biol Chem 272 : 19719 – 19724 , 1997 . 11 . Attar MA , Santy LC . The scaffolding protein GRASP / Tamalin directly binds to Dock180 as well as to cytohesins facilitating GTPase crosstalk in epithelial cell migration . BMC Cell Biol 14 : 2013 . Review 714 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m 12 . Bader GD , Cary MP , Sander C . Pathguide : a pathway resource list . Nucleic Acids Res 34 : D504 – D506 , 2006 . 13 . Balbin OA , Prensner JR , Sahu A , Yocum A , Shankar S , Malik R , Fermin D , Dhanasekaran SM , Chandler B , Thomas D , Beer DG , Cao X , Nesvizhskii AI , Chinnaiyan AM . Reconstructing targetable path - ways in lung cancer by integrating diverse omics data . Nat Commun 4 : 2617 , 2013 . 14 . Balkwill FR , Capasso M , Hagemann T . The tumor microenvironment at a glance . J Cell Sci 125 : 5591 – 5596 , 2012 . 15 . Baritaki S , Chapman A , Yeung K , Spandidos DA , Palladino M , Bonavida B . Inhibition of epithelial to mesenchymal transition in met - astatic prostate cancer cells by the novel proteasome inhibitor , NPI - 0052 : pivotal roles of Snail repression and RKIP induction . Oncogene 28 : 3573 – 3585 , 2009 . 16 . Barretina J , Caponigro G , Stransky N , Venkatesan K , Margolin AA , Kim S , Wilson CJ , Lehar J , Kryukov GV , Sonkin D , Reddy A , Liu M , Murray L , Berger MF , Monahan JE , Morais P , Meltzer J , Korejwa A , Jane - Valbuena J , Mapa FA , Thibault J , Bric - Furlong E , Raman P , Shipway A , Engels IH , Cheng J , Yu GK , Yu J , Aspesi P Jr , de Silva M , Jagtap K , Jones MD , Wang L , Hatton C , Palescandolo E , Gupta S , Mahan S , Sougnez C , Onofrio RC , Liefeld T , MacConaill L , Winckler W , Reich M , Li N , Mesirov JP , Gabriel SB , Getz G , Ardlie K , Chan V , Myer VE , Weber BL , Porter J , Warmuth M , Finan P , Harris JL , Meyerson M , Golub TR , Morrissey MP , Sellers WR , Schlegel R , Garraway LA . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity . Nature 483 : 603 – 607 , 2012 . 17 . Barrett T , Wilhite SE , Ledoux P , Evangelista C , Kim IF , To - mashevsky M , Marshall KA , Phillippy KH , Sherman PM , Holko M , Yefanov A , Lee H , Zhang NG , Robertson CL , Serova N , Davis S , Soboleva A . NCBI GEO : archive for functional genomics data sets - update . Nucleic Acids Res 41 : D991 – D995 , 2013 . 18 . Barthelemy - Brichant N , David JL , Bosquee L , Bury T , Seidel L , Albert A , Bartsch P , Baugnet - Mahieu L , Deneufbourg JM . Increased TGFbeta1 plasma level in patients with lung cancer : potential mecha - nisms . Eur J Clin Invest 32 : 193 – 198 , 2002 . 19 . Bartram U , Speer CP . The role of transforming growth factor beta in lung development and disease . Chest 125 : 754 – 765 , 2004 . 20 . Basik M , Aguilar - Mahecha A , Rousseau C , Diaz Z , Tejpar S , Spatz A , Greenwood CM , Batist G . Biopsies : next - generation biospecimens for tailoring therapy . Nat Rev Clin Oncol 10 : 437 – 450 , 2013 . 21 . Beck TN , Gabitova L , Serebriiskii IG . Targeted therapy : genomic approaches . In : Encyclopedia of Molecular Cell Biology and Molecular Medicine , edited by Meyers RA . Weinheim : Wiley - Blackwell , 2014 . 22 . Beck TN , Nicolas E , Kopp MC , Golemis EA . Adaptors for disorders of the brain ? The cancer signaling proteins NEDD9 , CASS4 , and PTK2B in Alzheimer’s disease . Oncoscience . In press . 23 . Bedard PL , Hansen AR , Ratain MJ , Siu LL . Tumour heterogeneity in the clinic . Nature 501 : 355 – 364 , 2013 . 24 . Begley CG , Ellis LM . Drug development : raise standards for preclinical cancer research . Nature 483 : 531 – 533 , 2012 . 25 . Ben - Porath I , Thomson MW , Carey VJ , Ge R , Bell GW , Regev A , Weinberg RA . An embryonic stem cell - like gene expression signature in poorly differentiated aggressive human tumors . Nat Genet 40 : 499 – 507 , 2008 . 26 . Benson DA , Cavanaugh M , Clark K , Karsch - Mizrachi I , Lipman DJ , Ostell J , Sayers EW . GenBank . Nucleic Acids Res 41 : D36 – D42 , 2013 . 27 . Benson DA , Clark K , Karsch - Mizrachi I , Lipman DJ , Ostell J , Sayers EW . GenBank . Nucleic Acids Res 42 : D32 – D37 , 2014 . 28 . Berg JS , Adams M , Nassar N , Bizon C , Lee K , Schmitt CP , Wil - helmsen KC , Evans JP . An informatics approach to analyzing the incidentalome . Genet Med 15 : 36 – 44 , 2013 . 29 . Berg JS , Khoury MJ , Evans JP . Deploying whole genome sequencing in clinical practice and public health : meeting the challenge one bin at a time . Genet Med 13 : 499 – 504 , 2011 . 30 . Berman H , Henrick K , Nakamura H . Announcing the worldwide Protein Data Bank . Nat Struct Mol Biol 10 : 980 – 980 , 2003 . 31 . Bettegowda C , Sausen M , Leary RJ , Kinde I , Wang YX , Agrawal N , Bartlett BR , Wang H , Luber B , Alani RM , Antonarakis ES , Azad NS , Bardelli A , Brem H , Cameron JL , Lee CC , Fecher LA , Gallia GL , Gibbs P , Le D , Giuntoli RL , Goggins M , Hogarty MD , Holdhoff M , Hong SM , Jiao YC , Juhl HH , Kim JJ , Siravegna G , Laheru DA , Lauricella C , Lim M , Lipson EJ , Marie SKN , Netto GJ , Oliner KS , Olivi A , Olsson L , Riggins GJ , Sartore - Bianchi A , Schmidt K , Shih IM , Oba - Shinjo SM , Siena S , Theodorescu D , Tie JN , Harkins TT , Veronese S , Wang TL , Weingart JD , Wolfgang CL , Wood LD , Xing DM , Hruban RH , Wu J , Allen PJ , Schmidt CM , Choti MA , Vel - culescu VE , Kinzler KW , Vogelstein B , Papadopoulos N , Luis AJ . Detection of circulating tumor DNA in early - and late - stage human malignancies . Sci Transl Med 6 : 224ra24 , 2014 . 32 . Bhowmick NA , Ghiassi M , Bakin A , Aakre M , Lundquist CA , Engel ME , Arteaga CL , Moses HL . Transforming growth factor - beta 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA - dependent mechanism . Mol Biol Cell 12 : 27 – 36 , 2001 . 33 . Bidard FC , Weigelt B , Reis JS . Going with the ﬂow : from circulating tumor cells to DNA . Sci Transl Med 5 : 207ps14 , 2013 . 34 . Blick T , Hugo H , Widodo E , Waltham M , Pinto C , Mani SA , Weinberg RA , Neve RM , Lenburg ME , Thompson EW . Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 ( hi / ) CD24 ( lo / - ) stem cell phenotype in human breast cancer . J Mammary Gland Biol 15 : 235 – 252 , 2010 . 35 . Botling J , Edlund K , Lohr M , Hellwig B , Holmberg L , Lambe M , Berglund A , Ekman S , Bergqvist M , Ponten F , Konig A , Fernandes O , Karlsson M , Helenius G , Karlsson C , Rahnenfuhrer J , Hengstler JG , Micke P . Biomarker discovery in non - small cell lung cancer : integrating gene expression proﬁling , meta - analysis , and tissue microar - ray validation . Clin Cancer Res 19 : 194 – 204 , 2013 . 36 . Bovelli D , Plataniotis G , Roila F . Cardiotoxicity of chemotherapeutic agents and radiotherapy - related heart disease : ESMO Clinical Practice Guidelines . Ann Oncol 21 , Suppl 5 : v277 – v282 , 2010 . 37 . Boyer BVA , Edme N . Induction and regulation of epithelial - mesenchy - mal transitions . Biochem Pharmacol 60 : 1091 – 1099 , 2000 . 38 . Bozic I , Reiter JG , Allen B , Antal T , Chatterjee K , Shah P , Moon YS , Yaqubie A , Kelly N , Le DT , Lipson EJ , Chapman PB , Diaz LA Jr , Vogelstein B , Nowak MA . Evolutionary dynamics of cancer in response to targeted combination therapy . eLife 2 : e00747 , 2013 . 39 . Buonato JM , Lazzara MJ . ERK1 / 2 blockade prevents epithelial - mes - enchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition . Cancer Res 74 : 309 – 319 , 2014 . 40 . Byers LA , Diao L , Wang J , Saintigny P , Girard L , Peyton M , Shen L , Fan Y , Giri U , Tumula PK , Nilsson MB , Gudikote J , Tran H , Cardnell RJ , Bearss DJ , Warner SL , Foulks JM , Kanner SB , Gandhi V , Krett N , Rosen ST , Kim ES , Herbst RS , Blumenschein GR , Lee JJ , Lippman SM , Ang KK , Mills GB , Hong WK , Weinstein JN , Wistuba II , Coombes KR , Minna JD , Heymach JV . An epithelial - mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identiﬁes Axl as a therapeutic target for overcoming EGFR inhibitor resistance . Clin Cancer Res 19 : 279 – 290 , 2013 . 41 . Cabodi S , del Pilar Camacho - Leal M , Di Stefano P , Deﬁlippi P . Integrin signalling adaptors : not only ﬁgurants in the cancer story . Nat Rev Cancer 10 : 858 – 870 , 2010 . 42 . Caldas C . Cancer sequencing unravels clonal evolution . Nat Biotechnol 30 : 408 – 410 , 2012 . 42a . Cancer Genome Atlas Research Network . Comprehensive genomic characterization of squamous cell lung cancers . Nature 489 : 519 – 525 , 2012 . 43 . Canel M , Serrels A , Frame MC , Brunton VG . E - cadherin - integrin crosstalk in cancer invasion and metastasis . J Cell Sci 126 : 393 – 401 , 2013 . 44 . Cano A , Perez - Moreno MA , Rodrigo I , Locascio A , Blanco MJ , del Barrio MG , Portillo F , Nieto MA . The transcription factor snail controls epithelial - mesenchymal transitions by repressing E - cadherin expression . Nat Cell Biol 2 : 76 – 83 , 2000 . 45 . Cardarella S , Johnson BE . The impact of genomic changes on treat - ment of lung cancer . Am J Respir Crit Care Med 188 : 770 – 775 , 2013 . 46 . Carretero J , Shimamura T , Rikova K , Jackson AL , Wilkerson MD , Borgman CL , Buttarazzi MS , Sanofsky BA , McNamara KL , Brand - stetter KA , Walton ZE , Gu TL , Silva JC , Crosby K , Shapiro GI , Maira SM , Ji HB , Castrillon DH , Kim CF , Garcia - Echeverria C , Bardeesy N , Sharpless NE , Hayes ND , Kim WY , Engelman JA , Wong KK . Integrative genomic and proteomic analyses identify targets for Lkb1 - deﬁcient metastatic lung tumors . Cancer Cell 17 : 547 – 559 , 2010 . 47 . Cerami E , Gao J , Dogrusoz U , Gross BE , Sumer SO , Aksoy BA , Jacobsen A , Byrne CJ , Heuer ML , Larsson E , Antipin Y , Reva B , Goldberg AP , Sander C , Schultz N . The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data . Cancer Discov 2 : 401 – 404 , 2012 . Review 715 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m 48 . Chaffer CL , Weinberg RA . A perspective on cancer cell metastasis . Science 331 : 1559 – 1564 , 2011 . 49 . Chang JX , Gao F , Zhao GQ , Zhang GJ . Role of NEDD9 in invasion and metastasis of lung adenocarcinoma . Exp Ther Med 4 : 795 – 800 , 2012 . 50 . Chang L , Graham PH , Hao J , Ni J , Bucci J , Cozzi PJ , Kearsley JH , Li Y . Acquisition of epithelial - mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K / Akt / mTOR pathway in prostate cancer radioresistance . Cell Death Dis 4 : e875 , 2013 . 51 . Chang MH , Lee K , Lee KY , Kim YS , Kim YK , Kang JH . Prognostic role of integrin beta1 , E - cadherin , and rac1 expression in small cell lung cancer . APMIS 120 : 28 – 38 , 2012 . 52 . Chang TH , Tsai MF , Su KY , Wu SG , Huang CP , Yu SL , Yu YL , Lan CC , Yang CH , Lin SB , Wu CP , Shih JY , Yang PC . Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhib - itor . Am J Respir Crit Care Med 183 : 1071 – 1079 , 2011 . 53 . Chao Y , Wu Q , Acquafondata M , Dhir R , Wells A . Partial mesen - chymal to epithelial reverting transition in breast and prostate cancer metastases . Cancer Microenvir 5 : 19 – 28 , 2012 . 54 . Charpidou AG , Gkiozos I , Tsimpoukis S , Apostolaki D , Dilana KD , Karapanagiotou EM , Syrigos KN . Therapy - induced toxicity of the lungs : an overview . Anticancer Res 29 : 631 – 639 , 2009 . 55 . Cheifetz S , Weatherbee JA , Tsang ML , Anderson JK , Mole JE , Lucas R , Massague J . The transforming growth factor - beta system , a complex pattern of cross - reactive ligands and receptors . Cell 48 : 409 – 415 , 1987 . 56 . Cheng L , Alexander RE , Maclennan GT , Cummings OW , Montironi R , Lopez - Beltran A , Cramer HM , Davidson DD , Zhang S . Molecular pathology of lung cancer : key to personalized medicine . Mod Pathol 25 : 347 – 369 , 2012 . 57 . Cheung KJ , Gabrielson E , Werb Z , Ewald AJ . Collective invasion in breast cancer requires a conserved basal epithelial program . Cell 155 : 1639 – 1651 , 2013 . 59 . Chin L , Andersen JN , Futreal PA . Cancer genomics : from discovery science to personalized medicine . Nat Med 17 : 297 – 303 , 2011 . 60 . Chin L , Hahn WC , Getz G , Meyerson M . Making sense of cancer genomic data . Genes Dev 25 : 534 – 555 , 2011 . 61 . Chmielecki J , Meyerson M . DNA sequencing of cancer : what have we learned ? Ann Rev Med 65 : 63 – 79 , 2014 . 61a . Clinical Lung Cancer Genome Project ( CLCGP ) ; Network Genomic Medicine ( NGM ) . A genomics - based classiﬁcation of human lung tu - mors . Sci Transl Med 5 : 209ra153 , 2013 . 62 . Coldren CD , Helfrich BA , Witta SE , Sugita M , Lapadat R , Zeng C , Baron A , Franklin WA , Hirsch FR , Geraci MW , Bunn PA Jr . Baseline gene expression predicts sensitivity to geﬁtinib in non - small cell lung cancer cell lines . Mol Cancer Res 4 : 521 – 528 , 2006 . 63 . Coletta A , Molter C , Duque R , Steenhoff D , Taminau J , de Schaetzen V , Meganck S , Lazar C , Venet D , Detours V , Nowe A , Bersini H , Weiss Solis DY . inSilico DB genomic datasets hub : an efﬁcient starting point for analyzing genome - wide studies in GenePattern , Integrative Genomics Viewer , and R / Bioconductor . Genome Biol 13 : R104 , 2012 . 64 . Creighton CJ , Gibbons DL , Kurie JM . The role of epithelial - mesen - chymal transition programming in invasion and metastasis : a clinical perspective . Cancer Manag Res 5 : 187 – 195 , 2013 . 65 . Croft D , Mundo AF , Haw R , Milacic M , Weiser J , Wu G , Caudy M , Garapati P , Gillespie M , Kamdar MR , Jassal B , Jupe S , Matthews L , May B , Palatnik S , Rothfels K , Shamovsky V , Song H , Williams M , Birney E , Hermjakob H , Stein L , D’Eustachio P . The Reactome pathway knowledgebase . Nucleic Acids Res 42 : D472 – D477 , 2014 . 66 . Cubillo E , Diaz - Lopez A , Cuevas EP , Moreno - Bueno G , Peinado H , Montes A , Santos V , Portillo F , Cano A . E47 and Id1 interplay in epithelial - mesenchymal transition . PLoS One 8 : e59948 , 2013 . 67 . Cuﬁi S , Bonavia R , Vazquez - Martin A , Oliveras - Ferraros C , Corominas - Faja B , Cuyas E , Martin - Castillo B , Barrajon - Catalan E , Visa J , Segura - Carretero A , Joven J , Bosch - Barrera J , Micol V , Menendez JA . Silibinin suppresses EMT - driven erlotinib resistance by reversing the high miR - 21 / low miR - 200c signature in vivo . Sci Rep 3 : 1 – 10 , 2013 . 68 . da Cunha Santos G , Shepherd FA , Tsao MS . EGFR mutations and lung cancer . Ann Rev Pathol 6 : 49 – 69 , 2011 . 69 . Dalerba P , Kalisky T , Sahoo D , Rajendran PS , Rothenberg ME , Leyrat AA , Sim S , Okamoto J , Johnston DM , Qian D , Zabala M , Bueno J , Neff NF , Wang J , Shelton AA , Visser B , Hisamori S , Shimono Y , van de Wetering M , Clevers H , Clarke MF , Quake SR . Single - cell dissection of transcriptional heterogeneity in human colon tumors . Nat Biotechnol 29 : 1120 – 1127 , 2011 . 70 . Davis AP , Wiegers TC , Roberts PM , King BL , Lay JM , Lennon - Hopkins K , Sciaky D , Johnson R , Keating H , Greene N , Hernandez R , McConnell KJ , Enayetallah AE , Mattingly CJ . A CTD - Pﬁzer collaboration : manual curation of 88 , 000 scientiﬁc articles text mined for drug - disease and drug - phenotype interactions . Database 2013 : bat080 , 2013 . 71 . Davis FM , Stewart TA , Thompson EW , Monteith GR . Targeting EMT in cancer : opportunities for pharmacological intervention . Trends Pharmacol Sci In Press , Corrected Proof . : 2014 . 72 . Diaz LA , Bardelli A . Liquid biopsies : genotyping circulating tumor DNA . J Clin Oncol 32 : 579 – 586 , 2014 . 73 . Diaz LA , Polyak K . Tracking tumor resistance using ‘liquid biopsies’ . Nat Med 19 : 676 – 677 , 2013 . 74 . Ding L , Getz G , Wheeler DA , Mardis ER , McLellan MD , Cibulskis K , Sougnez C , Greulich H , Muzny DM , Morgan MB , Fulton L , Fulton RS , Zhang Q , Wendl MC , Lawrence MS , Larson DE , Chen K , Dooling DJ , Sabo A , Hawes AC , Shen H , Jhangiani SN , Lewis LR , Hall O , Zhu Y , Mathew T , Ren Y , Yao J , Scherer SE , Clerc K , Metcalf GA , Ng B , Milosavljevic A , Gonzalez - Garay ML , Osborne JR , Meyer R , Shi X , Tang Y , Koboldt DC , Lin L , Abbott R , Miner TL , Pohl C , Fewell G , Haipek C , Schmidt H , Dunford - Shore BH , Kraja A , Crosby SD , Sawyer CS , Vickery T , Sander S , Robinson J , Winckler W , Baldwin J , Chirieac LR , Dutt A , Fennell T , Hanna M , Johnson BE , Onofrio RC , Thomas RK , Tonon G , Weir BA , Zhao X , Ziaugra L , Zody MC , Giordano T , Orringer MB , Roth JA , Spitz MR , Wistuba II , Ozenberger B , Good PJ , Chang AC , Beer DG , Watson MA , Ladanyi M , Broderick S , Yoshizawa A , Travis WD , Pao W , Province MA , Weinstock GM , Varmus HE , Gabriel SB , Lander ES , Gibbs RA , Meyerson M , Wilson RK . Somatic mutations affect key pathways in lung adenocarcinoma . Nature 455 : 1069 – 1075 , 2008 . 75 . Dinkel H , Chica C , Via A , Gould CM , Jensen LJ , Gibson TJ , Diella F . Phospho . ELM : a database of phosphorylation sites - update 2011 . Nucleic Acids Res 39 : D261 – D267 , 2011 . 76 . Dressman MA , Baras A , Malinowski R , Alvis LB , Kwon I , Walz TM , Polymeropoulos MH . Gene expression proﬁling detects gene ampliﬁ - cation and differentiates tumor types in breast cancer . Cancer Res 63 : 2194 – 2199 , 2003 . 77 . Druker BJ , Guilhot F , O’Brien SG , Gathmann I , Kantarjian H , Gattermann N , Deininger MW , Silver RT , Goldman JM , Stone RM , Cervantes F , Hochhaus A , Powell BL , Gabrilove JL , Rousselot P , Reiffers J , Cornelissen JJ , Hughes T , Agis H , Fischer T , Verhoef G , Shepherd J , Saglio G , Gratwohl A , Nielsen JL , Radich JP , Simons - son B , Taylor K , Baccarani M , So C , Letvak L , Larson RA . Five - year follow - up of patients receiving imatinib for chronic myeloid leukemia . N Engl J Med 355 : 2408 – 2417 , 2006 . 78 . Druker BJ , Sawyers CL , Kantarjian H , Resta DJ , Reese SF , Ford JM , Capdeville R , Talpaz M . Activity of a speciﬁc inhibitor of the BCR - ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome . N Engl J Med 344 : 1038 – 1042 , 2001 . 79 . Dudley JT , Butte AJ . In silico research in the era of cloud computing . Nat Biotechnol 28 : 1181 – 1185 , 2010 . 80 . Dumanskiy YV , Kudriashov AG , Vasilenko IV , Kondratyuk RB , Gulkov YK , Cyrillichystiakov RS . Markers of epithelial - mesenchymal transition in renal cell carcinoma . Exp Oncol 35 : 325 – 327 , 2013 . 81 . Duncan JS , Whittle MC , Nakamura K , Abell AN , Midland AA , Zawistowski JS , Johnson NL , Granger DA , Jordan NV , Darr DB , Usary J , Kuan PF , Smalley DM , Major B , He X , Hoadley KA , Zhou B , Sharpless NE , Perou CM , Kim WY , Gomez SM , Chen X , Jin J , Frye SV , Earp HS , Graves LM , Johnson GL . Dynamic reprogram - ming of the kinome in response to targeted MEK inhibition in triple - negative breast cancer . Cell 149 : 307 – 321 , 2012 . 82 . Eberwine J , Sul JY , Bartfai T , Kim J . The promise of single - cell sequencing . Nat Meth 11 : 25 – 27 , 2014 . 83 . Engelman JA , Zejnullahu K , Mitsudomi T , Song Y , Hyland C , Park JO , Lindeman N , Gale CM , Zhao X , Christensen J , Kosaka T , Holmes AJ , Rogers AM , Cappuzzo F , Mok T , Lee C , Johnson BE , Cantley LC , Janne PA . MET ampliﬁcation leads to geﬁtinib resistance in lung cancer by activating ERBB3 signaling . Science 316 : 1039 – 1043 , 2007 . 84 . Ettinger DS , Akerley W , Borghaei H , Chang AC , Cheney RT , Chirieac LR , D’Amico TA , Demmy TL , Ganti AK , Govindan R , Review 716 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m Grannis FW Jr , Horn L , Jahan TM , Jahanzeb M , Kessinger A , Komaki R , Kong FM , Kris MG , Krug LM , Lennes IT , Loo BW Jr , Martins R , O’Malley J , Osarogiagbon RU , Otterson GA , Patel JD , Pinder - Schenck MC , Pisters KM , Reckamp K , Riely GJ , Rohren E , Swanson SJ , Wood DE , Yang SC , Hughes M , Gregory KM . Non - small cell lung cancer . J Natl Compr Canc Netw 10 : 1236 – 1271 , 2012 . 85 . Ettinger DS , Akerley W , Borghaei H , Chang AC , Cheney RT , Chirieac LR , D’Amico TA , Demmy TL , Govindan R , Grannis FW Jr , Grant SC , Horn L , Jahan TM , Komaki R , Kong FM , Kris MG , Krug LM , Lackner RP , Lennes IT , Loo BW Jr , Martins R , Otterson GA , Patel JD , Pinder - Schenck MC , Pisters KM , Reckamp K , Riely GJ , Rohren E , Shapiro TA , Swanson SJ , Tauer K , Wood DE , Yang SC , Gregory K , Hughes M . Non - small cell lung cancer , version 2 . 2013 . J Natl Compr Canc Netw 11 : 645 – 653 , 2013 . 86 . Fashena SJ , Einarson MB , O’Neill GM , Patriotis C , Golemis EA . Dissection of HEF1 - dependent functions in motility and transcriptional regulation . J Cell Sci 115 : 99 – 111 , 2002 . 87 . Feng Y , Wang Y , Wang Z , Fang Z , Li F , Gao Y , Liu H , Xiao T , Li F , Zhou Y , Zhai Q , Liu X , Sun Y , Bardeesy N , Wong KK , Chen H , Xiong ZQ , Ji H . The CRTC1 - NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss . Cancer Res 72 : 6502 – 6511 , 2012 . 88 . Fischer JR , Darjes H , Lahm H , Schindel M , Drings P , Krammer PH . Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines . Eur J Cancer 30A : 2125 – 2129 , 1994 . 89 . Forbes SA , Bindal N , Bamford S , Cole C , Kok CY , Beare D , Jia M , Shepherd R , Leung K , Menzies A , Teague JW , Campbell PJ , Strat - ton MR , Futreal PA . COSMIC : mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer . Nucleic Acids Res 39 : D945 – D950 , 2011 . 90 . Frampton GM , Fichtenholtz A , Otto GA , Wang K , Downing SR , He J , Schnall - Levin M , White J , Sanford EM , An P , Sun J , Juhn F , Brennan K , Iwanik K , Maillet A , Buell J , White E , Zhao M , Balasubramanian S , Terzic S , Richards T , Banning V , Garcia L , Mahoney K , Zwirko Z , Donahue A , Beltran H , Mosquera JM , Rubin MA , Dogan S , Hedvat CV , Berger MF , Pusztai L , Lechner M , Boshoff C , Jarosz M , Vietz C , Parker A , Miller VA , Ross JS , Curran J , Cronin MT , Stephens PJ , Lipson D , Yelensky R . Development and validation of a clinical cancer genomic proﬁling test based on massively parallel DNA sequencing . Nat Biotechnol 31 : 1023 – 1031 , 2013 . 91 . Franceschini A , Szklarczyk D , Frankild S , Kuhn M , Simonovic M , Roth A , Lin J , Minguez P , Bork P , von Mering C , Jensen LJ . STRING V9 . 1 : protein - protein interaction networks , with increased cov - erage and integration . Nucleic Acids Res 41 : D808 – D815 , 2013 . 92 . Frederick BA , Helfrich BA , Coldren CD , Zheng D , Chan D , Bunn PA Jr , Raben D . Epithelial to mesenchymal transition predicts geﬁtinib resistance in cell lines of head and neck squamous cell carcinoma and non - small cell lung carcinoma . Mol Cancer Ther 6 : 1683 – 1691 , 2007 . 93 . Friboulet L , Li N , Katayama R , Lee CC , Gainor JF , Crystal AS , Michellys PY , Awad MM , Yanagitani N , Kim S , Pferdekamper AC , Li J , Kasibhatla S , Sun F , Sun X , Hua S , McNamara P , Mahmood S , Lockerman EL , Fujita N , Nishio M , Harris JL , Shaw AT , Engelman JA . The ALK inhibitor ceritinib overcomes crizotinib resistance in non - small cell lung cancer . Cancer Discov 4 : 662 – 673 , 2014 . 94 . Friedl P , Alexander S . Cancer invasion and the microenvironment : plasticity and reciprocity . Cell 147 : 992 – 1009 , 2011 . 95 . Friedl P , Locker J , Sahai E , Segall JE . Classifying collective cancer cell invasion . Nat Cell Biol 14 : 777 – 783 , 2012 . 96 . Friend SH , Norman TC . Metcalfe’s law and the biology information commons . Nat Biotechnol 31 : 297 – 303 , 2013 . 97 . Fujita Y , Krause G , Scheffner M , Zechner D , Leddy HE , Behrens J , Sommer T , Birchmeier W . Hakai , a c - Cbl - like protein , ubiquitinates and induces endocytosis of the E - cadherin complex . Nat Cell Biol 4 : 222 – 231 , 2002 . 98 . Fusaro VA , Mani DR , Mesirov JP , Carr SA . Prediction of high - responding peptides for targeted protein assays by mass spectrometry . Nat Biotechnol 27 : 190 – 198 , 2009 . 99 . Gao JJ , Aksoy BA , Dogrusoz U , Dresdner G , Gross B , Sumer SO , Sun YC , Jacobsen A , Sinha R , Larsson E , Cerami E , Sander C , Schultz N . Integrative analysis of complex cancer genomics and clinical proﬁles using the cBioPortal . Sci Signal 6 : pl1 , 2013 . 100 . Garnett MJ , Edelman EJ , Heidorn SJ , Greenman CD , Dastur A , Lau KW , Greninger P , Thompson IR , Luo X , Soares J , Liu Q , Iorio F , Surdez D , Chen L , Milano RJ , Bignell GR , Tam AT , Davies H , Stevenson JA , Barthorpe S , Lutz SR , Kogera F , Lawrence K , McLaren - Douglas A , Mitropoulos X , Mironenko T , Thi H , Richard - son L , Zhou W , Jewitt F , Zhang T , O’Brien P , Boisvert JL , Price S , Hur W , Yang W , Deng X , Butler A , Choi HG , Chang JW , Baselga J , Stamenkovic I , Engelman JA , Sharma SV , Delattre O , Saez - Rodri - guez J , Gray NS , Settleman J , Futreal PA , Haber DA , Stratton MR , Ramaswamy S , McDermott U , Benes CH . Systematic identiﬁcation of genomic markers of drug sensitivity in cancer cells . Nature 483 : 570 – 575 , 2012 . 101 . Garraway LA , Verweij J , Ballman KV . Precision oncology : an over - view . J Clin Oncol 31 : 1803 – 1805 , 2013 . 102 . Gemmill RM , Roche J , Potiron VA , Nasarre P , Mitas M , Coldren CD , Helfrich BA , Garrett - Mayer E , Bunn PA , Drabkin HA . ZEB1 - responsive genes in non - small cell lung cancer . Cancer Lett 300 : 66 – 78 , 2011 . 103 . Gentile A , Trusolino L , Comoglio PM . The Met tyrosine kinase receptor in development and cancer . Cancer Metastas Rev 27 : 85 – 94 , 2008 . 104 . Gentleman RC , Carey VJ , Bates DM , Bolstad B , Dettling M , Dudoit S , Ellis B , Gautier L , Ge YC , Gentry J , Hornik K , Hothorn T , Huber W , Iacus S , Irizarry R , Leisch F , Li C , Maechler M , Rossini AJ , Sawitzki G , Smith C , Smyth G , Tierney L , Yang JYH , Zhang JH . Bioconductor : open software development for computational biology and bioinformatics . Genome Biol 5 : R80 , 2004 . 105 . Gentry LR , Martin TD , Der CJ . Mechanisms of targeted therapy resistance take a de - TOR . Cancer Cell 24 : 284 – 286 , 2013 . 106 . Gerlinger M , Rowan AJ , Horswell S , Larkin J , Endesfelder D , Gronroos E , Martinez P , Matthews N , Stewart A , Tarpey P , Varela I , Phillimore B , Begum S , McDonald NQ , Butler A , Jones D , Raine K , Latimer C , Santos CR , Nohadani M , Eklund AC , Spencer - Dene B , Clark G , Pickering L , Stamp G , Gore M , Szallasi Z , Downward J , Futreal PA , Swanton C . Intratumor heterogeneity and branched evolu - tion revealed by multiregion sequencing . N Engl J Med 366 : 883 – 892 , 2012 . 107 . Gherardi E , Birchmeier W , Birchmeier C , Vande Woude G . Target - ing MET in cancer : rationale and progress . Nat Rev Cancer 12 : 89 – 103 , 2012 . 108 . Giaccone G , Zucali PA . Src as a potential therapeutic target in non - small - cell lung cancer . Ann Oncol 19 : 1219 – 1223 , 2008 . 109 . Giampieri S , Manning C , Hooper S , Jones L , Hill CS , Sahai E . Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility . Nat Cell Biol 11 : 1287 – 1296 , 2009 . 110 . Gibbons DL , Lin W , Creighton CJ , Rizvi ZH , Gregory PA , Goodall GJ , Thilaganathan N , Du LQ , Zhang YQ , Pertsemlidis A , Kurie JM . Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR - 200 family expression . Genes Dev 23 : 2140 – 2151 , 2009 . 111 . Glanzer JG , Eberwine JH . Expression proﬁling of small cellular samples in cancer : less is more . Br J Cancer 90 : 1111 – 1114 , 2004 . 112 . Gonzalez de Castro D , Clarke PA , Al - Lazikani B , Workman P . Personalized cancer medicine : molecular diagnostics , predictive bio - markers , and drug resistance . Clin Pharmacol Ther 93 : 252 – 259 , 2013 . 113 . Gonzalez - Perez A , Mustonen V , Reva B , Ritchie GR , Creixell P , Karchin R , Vazquez M , Fink JL , Kassahn KS , Pearson JV , Bader GD , Boutros PC , Muthuswamy L , Ouellette BF , Reimand J , Linding R , Shibata T , Valencia A , Butler A , Dronov S , Flicek P , Shannon NB , Carter H , Ding L , Sander C , Stuart JM , Stein LD , Lopez - Bigas N . Computational approaches to identify functional genetic variants in cancer genomes . Nat Meth 10 : 723 – 729 , 2013 . 114 . Govindan R , Ding L , Grifﬁth M , Subramanian J , Dees ND , Kanchi KL , Maher CA , Fulton R , Fulton L , Wallis J , Chen K , Walker J , McDonald S , Bose R , Ornitz D , Xiong D , You M , Dooling DJ , Watson M , Mardis ER , Wilson RK . Genomic landscape of non - small cell lung cancer in smokers and never - smokers . Cell 150 : 1121 – 1134 , 2012 . 115 . Grande M , Franzen A , Karlsson JO , Ericson LE , Heldin NE , Nilsson M . Transforming growth factor - beta and epidermal growth factor syn - ergistically stimulate epithelial to mesenchymal transition ( EMT ) through a MEK - dependent mechanism in primary cultured pig thyro - cytes . J Cell Sci 115 : 4227 – 4236 , 2002 . 116 . Greaves M , Maley CC . Clonal evolution in cancer . Nature 481 : 306 – 313 , 2012 . 117 . Gregory PA , Bert AG , Paterson EL , Barry SC , Tsykin A , Farshid G , Vadas MA , Khew - Goodall Y , Goodall GJ . The mir - 200 family and Review 717 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m mir - 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 . Nat Cell Biol 10 : 593 – 601 , 2008 . 118 . Guerrero MS , Parsons JT , Bouton AH . Cas and NEDD9 contribute to tumor progression through dynamic regulation of the cytoskeleton . Genes Cancer 3 : 371 – 381 , 2012 . 119 . Gumbiner BM , Mccrea PD . Catenins as mediators of the cytoplasmic functions of cadherins . J Cell Sci 155 – 158 , 1993 . 119a . Haibe - Kains B , El - Hachem N , Birkbak NJ , Jin AC , Beck AH , Aerts HJ , Quackenbush J . Inconsistency in large pharmacogenomic studies . Nature 504 : 389 – 393 , 2013 . 120 . Hart IR . New evidence for tumour embolism as a mode of metastasis . J Pathol 219 : 275 – 276 , 2009 . 121 . Hasegawa Y , Takanashi S , Kanehira Y , Tsushima T , Imai T , Oku - mura K . Transforming growth factor - beta1 level correlates with angio - genesis , tumor progression , and prognosis in patients with nonsmall cell lung carcinoma . Cancer 91 : 964 – 971 , 2001 . 122 . Hedenfalk IA , Ringner M , Trent JM , Borg A . Gene expression in inherited breast cancer . Adv Cancer Res 84 : 1 – 34 , 2002 . 123 . Hertz DL , McLeod HL . Use of pharmacogenetics for predicting cancer prognosis and treatment exposure , response and toxicity . J Hum Genet 58 : 346 – 352 , 2013 . 124 . Heuberger J , Birchmeier W . Interplay of cadherin - mediated cell adhe - sion and canonical Wnt signaling . Cold Spring Harbor Perspect Biol 2 : a002915 , 2010 . 125 . Hinz UUC . From protein sequences to 3D - structures and beyond : the example of the UniProt Knowledgebase . Cell Mol Life Sci 67 : 1049 – 1064 , 2010 . 126 . Hodoglugil U , Carrillo MW , Hebert JM , Karachaliou N , Rosell RC , Altman RB , Klein TE . PharmGKB summary : very important pharma - cogene information for the epidermal growth factor receptor . Pharma - cogenet Genomics 23 : 636 – 642 , 2013 . 127 . Hou JM , Krebs M , Ward T , Sloane R , Priest L , Hughes A , Clack G , Ranson M , Blackhall F , Dive C . Circulating tumor cells as a window on metastasis biology in lung cancer . Am J Pathol 178 : 989 – 996 , 2011 . 128 . Huang M , Shen AJ , Ding J , Geng MY . Molecularly targeted cancer therapy : some lessons from the past decade . Trends Pharmacol Sci 35 : 41 – 50 , 2014 . 129 . Huang Y , Gottardo R . Comparability and reproducibility of biomedical data . Brief Bioinformat 14 : 391 – 401 , 2013 . 130 . Hudson TJ , Anderson W , Artez A , Barker AD , Bell C , Bernabe RR , Bhan MK , Calvo F , Eerola I , Gerhard DS , Guttmacher A , Guyer M , Hemsley FM , Jennings JL , Kerr D , Klatt P , Kolar P , Kusada J , Lane DP , Laplace F , Youyong L , Nettekoven G , Ozenberger B , Peterson J , Rao TS , Remacle J , Schafer AJ , Shibata T , Stratton MR , Vockley JG , Watanabe K , Yang H , Yuen MM , Knoppers BM , Bobrow M , Cambon - Thomsen A , Dressler LG , Dyke SO , Joly Y , Kato K , Ken - nedy KL , Nicolas P , Parker MJ , Rial - Sebbag E , Romeo - Casabona CM , Shaw KM , Wallace S , Wiesner GL , Zeps N , Lichter P , Biankin AV , Chabannon C , Chin L , Clement B , de Alava E , Degos F , Ferguson ML , Geary P , Hayes DN , Hudson TJ , Johns AL , Kasprzyk A , Nakagawa H , Penny R , Piris MA , Sarin R , Scarpa A , Shibata T , van de Vijver M , Futreal PA , Aburatani H , Bayes M , Botwell DD , Campbell PJ , Estivill X , Gerhard DS , Grimmond SM , Gut I , Hirst M , Lopez - Otin C , Majumder P , Marra M , McPherson JD , Naka - gawa H , Ning Z , Puente XS , Ruan Y , Shibata T , Stratton MR , Stunnenberg HG , Swerdlow H , Velculescu VE , Wilson RK , Xue HH , Yang L , Spellman PT , Bader GD , Boutros PC , Campbell PJ , Flicek P , Getz G , Guigo R , Guo G , Haussler D , Heath S , Hubbard TJ , Jiang T , Jones SM , Li Q , Lopez - Bigas N , Luo R , Muthuswamy L , Ouellette BF , Pearson JV , Puente XS , Quesada V , Raphael BJ , Sander C , Shibata T , Speed TP , Stein LD , Stuart JM , Teague JW , Totoki Y , Tsunoda T , Valencia A , Wheeler DA , Wu H , Zhao S , Zhou G , Stein LD , Guigo R , Hubbard TJ , Joly Y , Jones SM , Kasprzyk A , Lathrop M , Lopez - Bigas N , Ouellette BF , Spellman PT , Teague JW , Thomas G , Valencia A , Yoshida T , Kennedy KL , Axton M , Dyke SO , Futreal PA , Gerhard DS , Gunter C , Guyer M , Hudson TJ , McPherson JD , Miller LJ , Ozenberger B , Shaw KM , Kasprzyk A , Stein LD , Zhang J , Haider SA , Wang J , Yung CK , Cros A , Liang Y , Gnaneshan S , Guberman J , Hsu J , Bobrow M , Chalmers DR , Hasel KW , Joly Y , Kaan TS , Kennedy KL , Knoppers BM , Lowrance WW , Masui T , Nicolas P , Rial - Sebbag E , Rodriguez LL , Vergely C , Yoshida T , Grimmond SM , Biankin AV , Bowtell DD , Cloonan N , deFazio A , Eshleman JR , Etemadmoghadam D , Gardiner BB , Kench JG , Scarpa A , Sutherland RL , Tempero MA , Waddell NJ , Wilson PJ , McPherson JD , Gallinger S , Tsao MS , Shaw PA , Petersen GM , Mukhopadhyay D , Chin L , DePinho RA , Thayer S , Muthuswamy L , Shazand K , Beck T , Sam M , Timms L , Ballin V , Lu Y , Ji J , Zhang X , Chen F , Hu X , Zhou G , Yang Q , Tian G , Zhang L , Xing X , Li X , Zhu Z , Yu Y , Yu J , Yang H , Lathrop M , Tost J , Brennan P , Holcatova I , Zaridze D , Brazma A , Egevard L , Prokhortchouk E , Banks RE , Uhlen M , Cambon - Thomsen A , Viksna J , Ponten F , Skryabin K , Stratton MR , Futreal PA , Birney E , Borg A , Borresen - Dale AL , Caldas C , Foekens JA , Martin S , Reis - Filho JS , Richardson AL , Sotiriou C , Stunnenberg HG , Thoms G , van de Vijver M , van’t Veer L , Calvo F , Birnbaum D , Blanche H , Boucher P , Boyault S , Chabannon C , Gut I , Masson - Jacquemier JD , Lathrop M , Pauporte I , Pivot X , Vincent - Salomon A , Tabone E , Theillet C , Thomas G , Tost J , Treilleux I , Calvo F , Bioulac - Sage P , Clement B , Decaens T , Degos F , Franco D , Gut I , Gut M , Heath S , Lathrop M , Samuel D , Thomas G , Zucman - Rossi J , Lichter P , Eils R , Brors B , Korbel JO , Korshunov A , Landgraf P , Lehrach H , Pﬁster S , Radlwimmer B , Reifenberger G , Taylor MD , von Kalle C , Majumder PP , Sarin R , Rao TS , Bhan MK , Scarpa A , Pederzoli P , Lawlor RA , Delledonne M , Bardelli A , Biankin AV , Grimmond SM , Gress T , Klimstra D , Zamboni G , Shibata T , Nakamura Y , Nakagawa H , Kusada J , Tsunoda T , Miyano S , Aburatani H , Kato K , Fujimoto A , Yoshida T , Campo E , Lopez - Otin C , Estivill X , Guigo R , de Sanjose S , Piris MA , Montserrat E , Gonzalez - Diaz M , Puente XS , Jares P , Valencia A , Himmelbauer H , Quesada V , Bea S , Stratton MR , Futreal PA , Campbell PJ , Vincent - Salomon A , Richardson AL , Reis - Filho JS , van de Vijver M , Thomas G , Masson - Jacquemier JD , Aparicio S , Borg A , Borresen - Dale AL , Caldas C , Foekens JA , Stunnenberg HG , van’t Veer L , Easton DF , Spellman PT , Martin S , Barker AD , Chin L , Collins FS , Compton CC , Ferguson ML , Gerhard DS , Getz G , Gunter C , Guttmacher A , Guyer M , Hayes DN , Lander ES , Ozen - berger B , Penny R , Peterson J , Sander C , Shaw KM , Speed TP , Spellman PT , Vockley JG , Wheeler DA , Wilson RK , Hudson TJ , Chin L , Knoppers BM , Lander ES , Lichter P , Stein LD , Stratton MR , Anderson W , Barker AD , Bell C , Bobrow M , Burke W , Collins FS , Compton CC , DePinho RA , Easton DF , Futreal PA , Gerhard DS , Green AR , Guyer M , Hamilton SR , Hubbard TJ , Kallioniemi OP , Kennedy KL , Ley TJ , Liu ET , Lu Y , Majumder P , Marra M , Ozenberger B , Peterson J , Schafer AJ , Spellman PT , Stunnenberg HG , Wainwright BJ , Wilson RK , Yang H . International network of cancer genome projects . Nature 464 : 993 – 998 , 2010 . 131 . Huh D , Hamilton GA , Ingber DE . From 3D cell culture to organs - on - chips . Trends Cell Biol 21 : 745 – 754 , 2011 . 132 . Huh D , Kim HJ , Fraser JP , Shea DE , Khan M , Bahinski A , Hamilton GA , Ingber DE . Microfabrication of human organs - on - chips . Nat Pro - tocols 8 : 2135 – 2157 , 2013 . 133 . Hussain F , Brimble E , Dickhout JG . The HDAC inhibitor , vorinastat , prevents TGF - beta 1 induced EMT and apoptosis in human renal prox - imal tubular cells . FASEB J 27 : 705 . 13 , 2013 . 134 . Ikushima H , Todo T , Ino Y , Takahashi M , Miyazawa K , Miyazono K . Autocrine TGF - beta signaling maintains tumorigenicity of glioma - initiating cells through Sry - Related HMG - box factors . Cell Stem Cell 5 : 504 – 514 , 2009 . 135 . Imielinski M , Berger AH , Hammerman PS , Hernandez B , Pugh TJ , Hodis E , Cho J , Suh J , Capelletti M , Sivachenko A , Sougnez C , Auclair D , Lawrence MS , Stojanov P , Cibulskis K , Choi K , de Waal L , Sharifnia T , Brooks A , Greulich H , Banerji S , Zander T , Seidel D , Leenders F , Ansen S , Ludwig C , Engel - Riedel W , Stoelben E , Wolf J , Goparju C , Thompson K , Winckler W , Kwiatkowski D , Johnson BE , Janne PA , Miller VA , Pao W , Travis WD , Pass HI , Gabriel SB , Lander ES , Thomas RK , Garraway LA , Getz G , Meyerson M . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing . Cell 150 : 1107 – 1120 , 2012 . 136 . Inamoto S , Iwata S , Inamoto T , Nomura S , Sasaki T , Urasaki Y , Hosono O , Kawasaki H , Tanaka H , Dang NH , Morimoto C . Crk - associated substrate lymphocyte type regulates transforming growth factor - beta signaling by inhibiting Smad6 and Smad7 . Oncogene 26 : 893 – 904 , 2007 . 137 . Ivanov AA , Khuri FR , Fu HA . Targeting protein - protein interactions as an anticancer strategy . Trends Pharmacol Sci 34 : 393 – 400 , 2013 . 138 . Izumchenko E , Singh MK , Plotnikova OV , Tikhmyanova N , Little JL , Serebriiskii IG , Seo S , Kurokawa M , Egleston BL , Klein - Szanto A , Pugacheva EN , Hardy RR , Wolfson M , Connolly DC , Golemis Review 718 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m EA . NEDD9 promotes oncogenic signaling in mammary tumor devel - opment . Cancer Res 69 : 7198 – 7206 , 2009 . 139 . Jin Y , Li F , Zheng C , Wang Y , Fang Z , Guo C , Wang X , Liu H , Deng L , Li C , Wang H , Chen H , Feng Y , Ji H . NEDD9 promotes lung cancer metastasis through epithelial - mesenchymal transition . Int J Cancer 134 : 2294 – 2304 , 2014 . 140 . Jing SW , Wang YD , Chen LQ , Sang MX , Zheng MM , Sun GG , Liu Q , Cheng YJ , Yang CR . Hypoxia suppresses E - cadherin and enhances matrix metalloproteinase - 2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor - 1 alpha activation . Dis Esophagus 26 : 75 – 83 , 2013 . 141 . Jing Y , Han Z , Liu Y , Sun K , Zhang S , Jiang G , Li R , Gao L , Zhao X , Wu D , Cai X , Wu M , Wei L . Mesenchymal stem cells in inﬂam - mation microenvironment accelerates hepatocellular carcinoma metasta - sis by inducing epithelial - mesenchymal transition . PLoS One 7 : e43272 , 2012 . 142 . Kalluri R , Neilson EG . Epithelial - mesenchymal transition and its im - plications for ﬁbrosis . J Clin Invest 112 : 1776 – 1784 , 2003 . 143 . Kalluri R , Weinberg RA . The basics of epithelial - mesenchymal tran - sition . J Clin Invest 119 : 1420 – 1428 , 2009 . 144 . Kan Z , Jaiswal BS , Stinson J , Janakiraman V , Bhatt D , Stern HM , Yue P , Haverty PM , Bourgon R , Zheng J , Moorhead M , Chaudhuri S , Tomsho LP , Peters BA , Pujara K , Cordes S , Davis DP , Carlton VE , Yuan W , Li L , Wang W , Eigenbrot C , Kaminker JS , Eberhard DA , Waring P , Schuster SC , Modrusan Z , Zhang Z , Stokoe D , de Sauvage FJ , Faham M , Seshagiri S . Diverse somatic mutation patterns and pathway alterations in human cancers . Nature 466 : 869 – 873 , 2010 . 145 . Kandoth C , McLellan MD , Vandin F , Ye K , Niu B , Lu C , Xie M , Zhang Q , McMichael JF , Wyczalkowski MA , Leiserson MD , Miller CA , Welch JS , Walter MJ , Wendl MC , Ley TJ , Wilson RK , Raphael BJ , Ding L . Mutational landscape and signiﬁcance across 12 major cancer types . Nature 502 : 333 – 339 , 2013 . 146 . Kanehisa M , Goto S , Hattori M , Aoki - Kinoshita KF , Itoh M , Ka - washima S , Katayama T , Araki M , Hirakawa M . From genomics to chemical genomics : new developments in KEGG . Nucleic Acids Res 34 : D354 – D357 , 2006 . 147 . Kanehisa M , Goto S , Sato Y , Furumichi M , Tanabe M . KEGG for integration and interpretation of large - scale molecular data sets . Nucleic Acids Res 40 : D109 – D114 , 2012 . 148 . Kapushesky M , Adamusiak T , Burdett T , Culhane A , Farne A , Filippov A , Holloway E , Klebanov A , Kryvych N , Kurbatova N , Kurnosov P , Malone J , Melnichuk O , Petryszak R , Pultsin N , Rustici G , Tikhonov A , Travillian RS , Williams E , Zorin A , Parkinson H , Brazma A . Gene Expression Atlas update – a value - added database of microarray and sequencing - based functional genomics experiments . Nu - cleic Acids Res 40 : D1077 – D1081 , 2012 . 149 . Kase S , Sugio K , Yamazaki K , Okamoto T , Yano T , Sugimachi K . Expression of E - cadherin and beta - catenin in human non - small cell lung cancer and the clinical signiﬁcance . Clin Cancer Res 6 : 4789 – 4796 , 2000 . 150 . Keedy VL , Temin S , Somerﬁeld MR , Beasley MB , Johnson DH , McShane LM , Milton DT , Strawn JR , Wakelee HA , Giaccone G . American Society of Clinical Oncology provisional clinical opinion : epidermal growth factor receptor ( EGFR ) Mutation testing for patients with advanced non - small - cell lung cancer considering ﬁrst - line EGFR tyrosine kinase inhibitor therapy . J Clin Oncol 29 : 2121 – 2127 , 2011 . 151 . Keshava Prasad TS , Goel R , Kandasamy K , Keerthikumar S , Ku - mar S , Mathivanan S , Telikicherla D , Raju R , Shafreen B , Venugo - pal A , Balakrishnan L , Marimuthu A , Banerjee S , Somanathan DS , Sebastian A , Rani S , Ray S , Harrys Kishore CJ , Kanth S , Ahmed M , Kashyap MK , Mohmood R , Ramachandra YL , Krishna V , Rahiman BA , Mohan S , Ranganathan P , Ramabadran S , Chaerkady R , Pan - dey A . Human Protein Reference Database – 2009 update . Nucleic Acids Res 37 : D767 – D772 , 2009 . 152 . Kim ES , Herbst RS , Wistuba II , Lee JJ , Blumenschein GR Jr , Tsao A , Stewart DJ , Hicks ME , Erasmus J Jr , Gupta S , Alden CM , Liu S , Tang X , Khuri FR , Tran HT , Johnson BE , Heymach JV , Mao L , Fossella F , Kies MS , Papadimitrakopoulou V , Davis SE , Lippman SM , Hong WK . The BATTLE trial : personalizing therapy for lung cancer . Cancer Discov 1 : 44 – 53 , 2011 . 153 . Kim M , Gans JD , Nogueira C , Wang A , Paik JH , Feng B , Brennan C , Hahn WC , Cordon - Cardo C , Wagner SN , Flotte TJ , Duncan LM , Granter SR , Chin L . Comparative oncogenomics identiﬁes NEDD9 as a melanoma metastasis gene . Cell 125 : 1269 – 1281 , 2006 . 154 . Kirk R . Targeted therapies : the maths behind combination therapy . Nat Rev Clin Oncol 10 : 488 , 2013 . 155 . Koedoot CG , de Haes JCJM , Heisterkamp SH , Bakker PJM , de Graeff A , de Haan RJ . Palliative chemotherapy or watchful waiting ? A vignettes study among oncologists . J Clin Oncol 20 : 3658 – 3664 , 2002 . 156 . Kong FM , Jirtle RL , Huang DH , Clough RW , Anscher MS . Plasma transforming growth factor - beta 1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma . Cancer 86 : 1712 – 1719 , 1999 . 157 . Kong FM , Washington MK , Jirtle RL , Anscher MS . Plasma trans - forming growth factor - beta 1 reﬂects disease status in patients with lung cancer after radiotherapy : a possible tumor marker . Lung Cancer 16 : 47 – 59 , 1996 . 158 . Kuehn H , Liberzon A , Reich M , Mesirov JP . Using GenePattern for gene expression analysis . Curr Protocols Bioinformat 7 : Unit 7 12 , 2008 . 159 . Kwak EL , Bang YJ , Camidge DR , Shaw AT , Solomon B , Maki RG , Ou SH , Dezube BJ , Janne PA , Costa DB , Varella - Garcia M , Kim WH , Lynch TJ , Fidias P , Stubbs H , Engelman JA , Sequist LV , Tan W , Gandhi L , Mino - Kenudson M , Wei GC , Shreeve SM , Ratain MJ , Settleman J , Christensen JG , Haber DA , Wilner K , Salgia R , Sha - piro GI , Clark JW , Iafrate AJ . Anaplastic lymphoma kinase inhibition in non - small - cell lung cancer . N Engl J Med 363 : 1693 – 1703 , 2010 . 160 . Labelle M , Begum S , Hynes RO . Direct signaling between platelets and cancer cells induces an epithelial - mesenchymal - like transition and pro - motes metastasis . Cancer Cell 20 : 576 – 590 , 2011 . 161 . Lackner MR , Wilson TR , Settleman J . Mechanisms of acquired resistance to targeted cancer therapies . Future Oncol 8 : 999 – 1014 , 2012 . 162 . Lamouille S , Subramanyam D , Blelloch R , Derynck R . Regulation of epithelial - mesenchymal and mesenchymal - epithelial transitions by mi - croRNAs . Curr Opin Cell Biol 25 : 200 – 207 , 2013 . 163 . Lamouille S , Xu J , Derynck R . Molecular mechanisms of epithelial - mesenchymal transition . Nat Rev Mol Cell Biol 15 : 178 – 196 , 2014 . 164 . Law SF , Estojak J , Wang B , Mysliwiec T , Kruh G , Golemis EA . Human enhancer of ﬁlamentation 1 , a novel p130cas - like docking pro - tein , associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae . Mol Cell Biol 16 : 3327 – 3337 , 1996 . 165 . Lawrence MS , Stojanov P , Polak P , Kryukov GV , Cibulskis K , Sivachenko A , Carter SL , Stewart C , Mermel CH , Roberts SA , Kiezun A , Hammerman PS , McKenna A , Drier Y , Zou L , Ramos AH , Pugh TJ , Stransky N , Helman E , Kim J , Sougnez C , Ambrogio L , Nickerson E , Sheﬂer E , Cortes ML , Auclair D , Saksena G , Voet D , Noble M , DiCara D , Lin P , Lichtenstein L , Heiman DI , Fennell T , Imielinski M , Hernandez B , Hodis E , Baca S , Dulak AM , Lohr J , Landau DA , Wu CJ , Melendez - Zajgla J , Hidalgo - Miranda A , Koren A , McCarroll SA , Mora J , Lee RS , Crompton B , Onofrio R , Parkin M , Winckler W , Ardlie K , Gabriel SB , Roberts CW , Biegel JA , Stegmaier K , Bass AJ , Garraway LA , Meyerson M , Golub TR , Gordenin DA , Sunyaev S , Lander ES , Getz G . Mutational heteroge - neity in cancer and the search for new cancer - associated genes . Nature 499 : 214 – 218 , 2013 . 166 . Le Meur N . Computational methods for evaluation of cell - based data assessment – Bioconductor . Curr Opin Biotechnol 24 : 105 – 111 , 2013 . 167 . Le Meur N , Gentleman R . Analyzing biological data using R : methods for graphs and networks . Meth Mol Biol 804 : 343 – 373 , 2012 . 168 . Le Tourneau C , Paoletti X , Servant N , Bieche I , Gentien D , Rio Frio T , Vincent - Salomon A , Servois V , Romejon J , Mariani O , Bernard V , Huppe P , Pierron G , Mulot F , Callens C , Wong J , Mauborgne C , Rouleau E , Reyes C , Henry E , Leroy Q , Gestraud P , La Rosa P , Escalup L , Mitry E , Tredan O , Delord JP , Campone M , Goncalves A , Isambert N , Gavoille C , Kamal M . Randomised proof - of - concept phase II trial comparing targeted therapy based on tumour molecular proﬁling vs conventional therapy in patients with refractory cancer : results of the feasibility part of the SHIVA trial . Br J Cancer 111 : 17 – 24 , 2014 . 169 . Lecharpentier A , Vielh P , Perez - Moreno P , Planchard D , Soria JC , Farace F . Detection of circulating tumour cells with a hybrid ( epithelial / mesenchymal ) phenotype in patients with metastatic non - small cell lung cancer . Br J Cancer 105 : 1338 – 1341 , 2011 . 170 . Lee JM , Dedhar S , Kalluri R , Thompson EW . The epithelial - mesen - chymal transition : new insights in signaling , development , and disease . J Cell Biol 172 : 973 – 981 , 2006 . 171 . Lee KH , Johmura Y , Yu LR , Park JE , Gao Y , Bang JK , Zhou M , Veenstra TD , Yeon Kim B , Lee KS . Identiﬁcation of a novel Wnt5a - Review 719 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m CK1varepsilon - Dvl2 - Plk1 - mediated primary cilia disassembly pathway . EMBO J 31 : 3104 – 3117 , 2012 . 172 . Li XQ , Yang XL , Zhang G , Wu SP , Deng XB , Xiao SJ , Liu QZ , Yao KT , Xiao GH . Nuclear beta - catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non - small cell lung cancer . J Transl Med 11 : 114 , 2013 . 173 . Linding R , Jensen LJ , Ostheimer GJ , van Vugt MA , Jorgensen C , Miron IM , Diella F , Colwill K , Taylor L , Elder K , Metalnikov P , Nguyen V , Pasculescu A , Jin J , Park JG , Samson LD , Woodgett JR , Russell RB , Bork P , Yaffe MB , Pawson T . Systematic discovery of in vivo phosphorylation networks . Cell 129 : 1415 – 1426 , 2007 . 174 . Liu H , Beck TN , Golemis EA , Serebriiskii IG . Integrating in silico resources to map a signaling network . Meth Mol Biol 1101 : 197 – 245 , 2014 . 175 . Liu H , Cracchiolo JR , Beck TN , Serebriiskii IG , Golemis EA . EGFR inhibitors as therapeutic agents in head and neck cancer . In : Molecular Determinants of Head and Neck Cancer , edited by Burtness B , Golemis EA . New York : Springer , 2014 , p . 55 – 90 . 176 . Liu SL , Cong Y , Wang D , Sun Y , Deng L , Liu YJ , Martin - Trevino R , Shang L , McDermott SP , Landis MD , Hong S , Adams A , D’Angelo R , Ginestier C , Charafe - Jauffret E , Clouthier SG , Birn - baum D , Wong ST , Zhan M , Chang JC , Wicha MS . Breast cancer stem cells transition between epithelial and mesenchymal states reﬂective of their normal counterparts . Stem Cell Rep 2 : 78 – 91 , 2014 . 177 . Liu X , Elia AE , Law SF , Golemis EA , Farley J , Wang T . A novel ability of Smad3 to regulate proteasomal degradation of a Cas family member HEF1 . EMBO J 19 : 6759 – 6769 , 2000 . 178 . Liu YN , Lee WW , Wang CY , Chao TH , Chen Y , Chen JH . Regula - tory mechanisms controlling human E - cadherin gene expression . Onco - gene 24 : 8277 – 8290 , 2005 . 179 . Lu X , Law BK , Chytil AM , Brown KA , Aakre ME , Moses HL . Activation of the Erk pathway is required for TGF - beta 1 - induced EMT in vitro . Neoplasia 6 : 603 – 610 , 2004 . 180 . Luis - Ravelo D , Anton I , Zandueta C , Valencia K , Ormazabal C , Martinez - Canarias S , Guruceaga E , Perurena N , Vicent S , De Las Rivas J , Lecanda F . A gene signature of bone metastatic colonization sensitizes for tumor - induced osteolysis and predicts survival in lung cancer . Oncogene [ Epub ahead of print ] . 181 . Ma L , Young J , Prabhala H , Pan E , Mestdagh P , Muth D , Teruya - Feldstein J , Reinhardt F , Onder TT , Valastyan S , Westermann F , Speleman F , Vandesompele J , Weinberg RA . miR - 9 , a MYC / MYCN - activated microRNA , regulates E - cadherin and cancer metastasis . Nat Cell Biol 12 : 247 – 256 , 2010 . 182 . MacDonald BT , Tamai K , He X . Wnt / beta - catenin signaling : compo - nents , mechanisms , and diseases . Dev Cell 17 : 9 – 26 , 2009 . 183 . Magee JA , Piskounova E , Morrison SJ . Cancer stem cells : impact , heterogeneity , and uncertainty . Cancer Cell 21 : 283 – 296 , 2012 . 184 . Mani SA , Guo W , Liao MJ , Eaton EN , Ayyanan A , Zhou AY , Brooks M , Reinhard F , Zhang CC , Shipitsin M , Campbell LL , Polyak K , Brisken C , Yang J , Weinberg RA . The epithelial - mesenchymal tran - sition generates cells with properties of stem cells . Cell 133 : 704 – 715 , 2008 . 185 . Manie SN , Beck ARP , Astier A , Law SF , Canty T , Hirai H , Druker BJ , Avraham H , Haghayeghi N , Sattler M , Salgia R , Grifﬁn JD , Golemis EA , Freedman AS . Involvement of p130 ( Cas ) and p105 ( HEF1 ) , a novel Cas - like docking protein , in a cytoskeleton - depen - dent signaling pathway initiated by ligation of integrin or antigen recep - tor on human B cells . J Biol Chem 272 : 4230 – 4236 , 1997 . 186 . Marshall HM , Leong SC , Bowman RV , Yang IA , Fong KM . The science behind the 7th edition Tumour , Node , Metastasis staging system for lung cancer . Respirology 17 : 247 – 260 , 2012 . 187 . Massague J . TGFbeta in cancer . Cell 134 : 215 – 230 , 2008 . 188 . Massague J . TGFbeta signalling in context . Nat Rev Mol Cell Biol 13 : 616 – 630 , 2012 . 189 . McDonald OG , Wu H , Timp W , Doi A , Feinberg AP . Genome - scale epigenetic reprogramming during epithelial - to - mesenchymal transition . Nat Struct Mol Biol 18 : 867 – 874 , 2011 . 190 . McFarland CD , Korolev KS , Kryukov GV , Sunyaev SR , Mirny LA . Impact of deleterious passenger mutations on cancer progression . Proc Natl Acad Sci USA 110 : 2910 – 2915 , 2013 . 191 . McLeod HL . Cancer pharmacogenomics : early promise , but concerted effort needed . Science 339 : 1563 – 1566 , 2013 . 192 . Meacham CE , Morrison SJ . Tumour heterogeneity and cancer cell plasticity . Nature 501 : 328 – 337 , 2013 . 193 . Medina I , Carbonell J , Pulido L , Madeira SC , Goetz S , Conesa A , Tarraga J , Pascual - Montano A , Nogales - Cadenas R , Santoyo J , Garcia F , Marba M , Montaner D , Dopazo J . Babelomics : an integra - tive platform for the analysis of transcriptomics , proteomics and genomic data with advanced functional proﬁling . Nucleic Acids Res 38 : W210 – W213 , 2010 . 194 . Mejlvang J , Kriajevska M , Vandewalle C , Chernova T , Sayan AE , Berx G , Mellon JK , Tulchinsky E . Direct repression of cyclin d1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition . Mol Biol Cell 18 : 4615 – 4624 , 2007 . 195 . Meyerson M , Gabriel S , Getz G . Advances in understanding cancer genomes through second - generation sequencing . Nat Rev Genet 11 : 685 – 696 , 2010 . 196 . Miao Y , Li AL , Wang L , Fan CF , Zhang XP , Xu HT , Yang LH , Liu Y , Wang EH . Overexpression of NEDD9 is associated with altered expression of E - Cadherin , beta - Catenin and N - cadherin and predictive of poor prognosis in non - small cell lung cancer . Pathol Oncol Res 19 : 281 – 286 , 2013 . 197 . Milius D , Dove ES , Chalmers D , Dyke SOM , Kato K , Nicolas P , Ouellette BFF , Ozenberger B , Rodriguez LL , Zeps N , Joly Y . The International Cancer Genome Consortium’s evolving data - protection policies . Nat Biotechnol 32 : 519 – 523 , 2014 . 198 . Mitsudomi T , Morita S , Yatabe Y , Negoro S , Okamoto I , Tsurutani J , Seto T , Satouchi M , Tada H , Hirashima T , Asami K , Katakami N , Takada M , Yoshioka H , Shibata K , Kudoh S , Shimizu E , Saito H , Toyooka S , Nakagawa K , Fukuoka M . Geﬁtinib versus cisplatin plus docetaxel in patients with non - small - cell lung cancer harbouring muta - tions of the epidermal growth factor receptor ( WJTOG3405 ) : an open label , randomised phase 3 trial . Lancet Oncol 11 : 121 – 128 , 2010 . 199 . Mootha VK , Lindgren CM , Eriksson KF , Subramanian A , Sihag S , Lehar J , Puigserver P , Carlsson E , Ridderstrale M , Laurila E , Houstis N , Daly MJ , Patterson N , Mesirov JP , Golub TR , Tamayo P , Spiegelman B , Lander ES , Hirschhorn JN , Altshuler D , Groop LC . PGC - 1alpha - responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes . Nat Genet 34 : 267 – 273 , 2003 . 200 . Moreno - Bueno G , Peinado H , Molina P , Olmeda D , Cubillo E , Santos V , Palacios J , Portillo F , Cano A . The morphological and molecular features of the epithelial - to - mesenchymal transition . Nat Pro - tocols 4 : 1591 – 1613 , 2009 . 201 . Morimoto K , Tanaka T , Nitta Y , Ohnishi K , Kawashima H , Naka - tani T . NEDD9 crucially regulates TGF - beta - triggered epithelial - mes - enchymal transition and cell invasion in prostate cancer cells : involve - ment in cancer progressiveness . Prostate 74 : 901 – 910 , 2014 . 202 . Mwenifumbo JC , Marra MA . Cancer genome - sequencing study de - sign . Nat Rev Genetics 14 : 321 – 332 , 2013 . 203 . Nagai T , Arao T , Furuta K , Sakai K , Kudo K , Kaneda H , Tamura D , Aomatsu K , Kimura H , Fujita Y , Matsumoto K , Saijo N , Kudo M , Nishio K . Sorafenib inhibits the hepatocyte growth factor - mediated epithelial mesenchymal transition in hepatocellular carcinoma . Mol Can - cer Ther 10 : 169 – 177 , 2011 . 204 . Nakata S , Sugio K , Uramoto H , Oyama T , Hanagiri T , Morita M , Yasumoto K . The methylation status and protein expression of CDH1 , p16 ( INK4A ) , and fragile histidine triad in nonsmall cell lung carcinoma : epigenetic silencing , clinical features , and prognostic signiﬁcance . Can - cer 106 : 2190 – 2199 , 2006 . 205 . Nakaya Y , Sukowati EW , Wu Y , Sheng G . RhoA and microtubule dynamics control cell - basement membrane interaction in EMT during gastrulation . Nat Cell Biol 10 : 765 – 775 , 2008 . 206 . Nam JS , Ino Y , Sakamoto M , Hirohashi S . Src family kinase inhibitor PP2 restores the E - cadherin / catenin cell adhesion system in human cancer cells and reduces cancer metastasis . Clin Cancer Res 8 : 2430 – 2436 , 2002 . 207 . Nature . Microarray standards at last . Nature 419 : 323 – 323 , 2002 . 208 . Navin N , Kendall J , Troge J , Andrews P , Rodgers L , McIndoo J , Cook K , Stepansky A , Levy D , Esposito D , Muthuswamy L , Krasnitz A , McCombie WR , Hicks J , Wigler M . Tumour evolution inferred by single - cell sequencing . Nature 472 : 90 – 94 , 2011 . 209 . Nazareth MR , Broderick L , Simpson - Abelson MR , Kelleher RJ Jr , Yokota SJ , Bankert RB . Characterization of human lung tumor - asso - ciated ﬁbroblasts and their ability to modulate the activation of tumor - associated T cells . J Immunol 178 : 5552 – 5562 , 2007 . Review 720 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m 210 . NCBI Resource Coordinators . Database resources of the National Center for Biotechnology Information . Nucleic Acids Res 42 : D7 – D17 , 2014 . 213 . Nguyen DX , Bos PD , Massague J . Metastasis : from dissemination to organ - speciﬁc colonization . Nat Rev Cancer 9 : 274 - U265 , 2009 . 214 . Nieto MA . Epithelial plasticity : a common theme in embryonic and cancer cells . Science 342 : 1234850 , 2013 . 215 . Nieto MA . The ins and outs of the epithelial to mesenchymal transition in health and disease . Ann Rev Cell Dev Biol 27 : 347 – 376 , 2011 . 216 . Nikonova AS , Gaponova AV , Kudinov AE , Golemis EA . CAS pro - teins in health and disease : an update . IUBMB Life 66 : 387 – 395 , 2014 . 217 . Nikonova AS , Gaponova AV , Kudinov AE , Golemis EA . CAS pro - teins in health and disease : an update . IUBMB Life 66 : 387 – 395 , 2014 . 218 . Noble WS . How does multiple testing correction work ? Nat Biotechnol 27 : 1135 – 1137 , 2009 . 219 . Nose A , Takeichi M . A novel cadherin cell adhesion molecule : its expression patterns associated with implantation and organogenesis of mouse embryos . J Cell Biol 103 : 2649 – 2658 , 1986 . 220 . Nowell PC , Hungerford DA . Chromosome studies on normal and leukemic human leukocytes . J Natl Cancer Inst 25 : 85 – 109 , 1960 . 221 . Nurwidya F , Takahashi F , Murakami A , Takahashi K . Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer . Cancer Res Treat 44 : 151 – 156 , 2012 . 222 . O’Neill GM , Seo S , Serebriiskii IG , Lessin SR , Golemis EA . A new central scaffold for metastasis : parsing HEF1 / Cas - L / NEDD9 . Cancer Res 67 : 8975 – 8979 , 2007 . 223 . Ohashi K , Sequist LV , Arcila ME , Moran T , Chmielecki J , Lin YL , Pan Y , Wang L , de Stanchina E , Shien K , Aoe K , Toyooka S , Kiura K , Fernandez - Cuesta L , Fidias P , Yang JC , Miller VA , Riely GJ , Kris MG , Engelman JA , Vnencak - Jones CL , Dias - Santagata D , Ladanyi M , Pao W . Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS , NRAS , or MEK1 . Proc Natl Acad Sci USA 109 : E2127 – E2133 , 2012 . 224 . Oskarsson T , Batlle E , Massague J . Metastatic stem cells : sources , niches , and vital pathways . Cell Stem Cell 14 : 306 – 321 , 2014 . 225 . Ozawa M , Baribault H , Kemler R . The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent pro - teins structurally related in different species . EMBO J 8 : 1711 – 1717 , 1989 . 226 . Paredes J , Figueiredo J , Albergaria A , Oliveira P , Carvalho J , Ribeiro AS , Caldeira J , Costa AM , Simoes - Correia J , Oliveira MJ , Pinheiro H , Pinho SS , Mateus R , Reis CA , Leite M , Fernandes MS , Schmitt F , Carneiro F , Figueiredo C , Oliveira C , Seruca R . Epithelial E - and P - cadherins : role and clinical signiﬁcance in cancer . Biochim Biophys Acta 1826 : 297 – 311 , 2012 . 227 . Park SM , Gaur AB , Lengyel E , Peter ME . The miR - 200 family determines the epithelial phenotype of cancer cells by targeting the E - cadherin repressors ZEB1 and ZEB2 . Genes Dev 22 : 894 – 907 , 2008 . 228 . Patnaik SK , Kannisto E , Knudsen S , Yendamuri S . Evaluation of microRNA expression proﬁles that may predict recurrence of localized stage I non - small cell lung cancer after surgical resection . Cancer Res 70 : 36 – 45 , 2010 . 229 . Pattabiraman DR , Weinberg RA . Tackling the cancer stem cells - what challenges do they pose ? Nature Reviews Drug Discovery 13 : 497 – 512 , 2014 . 230 . Perera M , Tsang CS , Distel RJ , Lacy JN , Ohno - Machado L , Ric - chiuti V , Samaranayake LP , Smejkal GB , Smith MG , Trachtenberg AJ , Kuo WP . TGF - beta1 interactome : metastasis and beyond . Cancer Genom Proteom 7 : 217 – 229 , 2010 . 231 . Petryszak R , Burdett T , Fiorelli B , Fonseca NA , Gonzalez - Porta M , Hastings E , Huber W , Jupp S , Keays M , Kryvych N , McMurry J , Marioni JC , Malone J , Megy K , Rustici G , Tang AY , Taubert J , Williams E , Mannion O , Parkinson HE , Brazma A . Expression Atlas update – a database of gene and transcript expression from microarray - and sequencing - based functional genomics experiments . Nucleic Acids Res 42 : D926 – D932 , 2014 . 232 . Pickup M , Novitskiy S , Moses HL . The roles of TGFbeta in the tumour microenvironment . Nat Rev Cancer 13 : 788 – 799 , 2013 . 233 . Pirozzi G , Tirino V , Camerlingo R , Franco R , La Rocca A , Liguori E , Martucci N , Paino F , Normanno N , Rocco G . Epithelial to mesen - chymal transition by TGFbeta - 1 induction increases stemness character - istics in primary non - small cell lung cancer cell line . PLoS One 6 : e21548 , 2011 . 234 . Pittet MJ , Weissleder R . Intravital imaging . Cell 147 : 983 – 991 , 2011 . 235 . Pokutta S , Herrenknecht K , Kemler R , Engel J . Conformational changes of the recombinant extracellular domain of E - cadherin upon calcium binding . Eur J Biochem 223 : 1019 – 1026 , 1994 . 236 . Pokutta S , Weis WI . Structure and mechanism of cadherins and catenins in cell - cell contacts . Ann Rev Cell Dev Biol 23 : 237 – 261 , 2007 . 237 . Polyak K , Weinberg RA . Transitions between epithelial and mesenchy - mal states : acquisition of malignant and stem cell traits . Nat Rev Cancer 9 : 265 – 273 , 2009 . 238 . Portella G , Cumming SA , Liddell J , Cui W , Ireland H , Akhurst RJ , Balmain A . Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo : Implications for tumor invasion . Cell Growth Differ 9 : 393 – 404 , 1998 . 239 . Potter NE , Ermini L , Papaemmanuil E , Cazzaniga G , Vijayaragha - van G , Titley I , Ford A , Campbell P , Kearney L , Greaves M . Single - cell mutational proﬁling and clonal phylogeny in cancer . Genome Res 23 : 2115 – 2125 , 2013 . 240 . Potter NE , Ermini L , Papaemmanuil E , Cazzaniga G , Vijayaragha - van G , Titley I , Ford A , Campbell P , Kearney L , Greaves M . Single - cell mutational proﬁling and clonal phylogeny in cancer . Genome Res 23 : 2115 – 2125 , 2013 . 241 . Pratilas CA , Hanrahan AJ , Halilovic E , Persaud Y , Soh J , Chitale D , Shigematsu H , Yamamoto H , Sawai A , Janakiraman M , Taylor BS , Pao W , Toyooka S , Ladanyi M , Gazdar A , Rosen N , Solit DB . Genetic predictors of MEK dependence in non - small cell lung cancer . Cancer Res 68 : 9375 – 9383 , 2008 . 242 . Puls LN , Eadens M , Messersmith W . Current status of SRC inhibitors in solid tumor malignancies . Oncologist 16 : 566 – 578 , 2011 . 243 . Punta M , Coggill PC , Eberhardt RY , Mistry J , Tate J , Boursnell C , Pang N , Forslund K , Ceric G , Clements J , Heger A , Holm L , Sonnhammer EL , Eddy SR , Bateman A , Finn RD . The Pfam protein families database . Nucleic Acids Res 40 : D290 – D301 , 2012 . 244 . Pyne S , Hu X , Wang K , Rossin E , Lin TI , Maier LM , Baecher - Allan C , McLachlan GJ , Tamayo P , Haﬂer DA , De Jager PL , Mesirov JP . Automated high - dimensional ﬂow cytometric data analysis . Proc Natl Acad Sci USA 106 : 8519 – 8524 , 2009 . 245 . Quail DF , Joyce JA . Microenvironmental regulation of tumor progres - sion and metastasis . Nat Med 19 : 1423 – 1437 , 2013 . 246 . Rahman N . Realizing the promise of cancer predisposition genes . Nature 505 : 302 – 308 , 2014 . 247 . Ratushny V , Pathak HB , Beeharry N , Tikhmyanova N , Xiao F , Li T , Litwin S , Connolly DC , Yen TJ , Weiner LM , Godwin AK , Golemis EA . Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death . Oncogene 31 : 1217 – 1227 , 2012 . 248 . Reich M , Liefeld T , Gould J , Lerner J , Tamayo P , Mesirov JP . GenePattern 20 . Nat Genet 38 : 500 – 501 , 2006 . 249 . Reka AK , Chen G , Jones RC , Amunugama R , Kim S , Karnovsky A , Standiford TJ , Beer DG , Omenn GS , Keshamouni VG . Epithelial - mesenchymal transition - associated secretory phenotype predicts survival in lung cancer patients . Carcinogenesis 35 : 1292 – 1300 , 2014 . 250 . Ren J , Chen Y , Song H , Chen L , Wang R . Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel - resistant human lung adenocar - cinoma cell line . J Cell Biochem 114 : 1395 – 1403 , 2013 . 251 . Rhim AD , Mirek ET , Aiello NM , Maitra A , Bailey JM , McAllister F , Reichert M , Beatty GL , Rustgi AK , Vonderheide RH , Leach SD , Stanger BZ . EMT and dissemination precede pancreatic tumor forma - tion . Cell 148 : 349 – 361 , 2012 . 252 . Rhodes DR , Kalyana - Sundaram S , Mahavisno V , Varambally R , Yu J , Briggs BB , Barrette TR , Anstet MJ , Kincead - Beal C , Kulkarni P , Varambally S , Ghosh D , Chinnaiyan AM . Oncomine 3 . 0 : genes , pathways , and networks in a collection of 18 , 000 cancer gene expression proﬁles . Neoplasia 9 : 166 – 180 , 2007 . 253 . Riggleman B , Schedl P , Wieschaus E . Spatial expression of the Dro - sophila segment polarity gene armadillo is posttranscriptionally regulated by wingless . Cell 63 : 549 – 560 , 1990 . 254 . Roberts AB , Wakeﬁeld LM . The two faces of transforming growth factor beta in carcinogenesis . Proc Natl Acad Sci USA 100 : 8621 – 8623 , 2003 . 255 . Robinson JT , Thorvaldsdottir H , Winckler W , Guttman M , Lander ES , Getz G , Mesirov JP . Integrative genomics viewer . Nat Biotechnol 29 : 24 – 26 , 2011 . 256 . Rustici G , Kolesnikov N , Brandizi M , Burdett T , Dylag M , Emam I , Farne A , Hastings E , Ison J , Keays M , Kurbatova N , Malone J , Mani R , Mupo A , Pedro Pereira R , Pilicheva E , Rung J , Sharma A , Tang Review 721 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m YA , Ternent T , Tikhonov A , Welter D , Williams E , Brazma A , Parkinson H , Sarkans U . ArrayExpress update – trends in database growth and links to data analysis tools . Nucleic Acids Res 41 : D987 – D990 , 2013 . 257 . Salonon - Ferrer R , Case DA , Walker RC . An overview of the Amber biomolecular simulation package . Comp Chem Mol Model 3 : 198 – 210 , 2013 . 258 . Sanchez - Tillo E , Liu YQ , de Barrios O , Siles L , Fanlo L , Cuatrecasas M , Darling DS , Dean DC , Castells A , Postigo A . EMT - activating transcription factors in cancer : beyond EMT and tumor invasiveness . Cell Mol Life Sci 69 : 3429 – 3456 , 2012 . 259 . Sanz - Moreno V . Tumour invasion : a new twist on Rac - driven mesen - chymal migration . Curr Biol 22 : R449 – R451 , 2012 . 260 . Sanz - Moreno V , Gadea G , Ahn J , Paterson H , Marra P , Pinner S , Sahai E , Marshall CJ . Rac activation and inactivation control plasticity of tumor cell movement . Cell 135 : 510 – 523 , 2008 . 261 . Sarrio D , Rodriguez - Pinilla SM , Hardisson D , Cano A , Moreno - Bueno G , Palacios J . Epithelial - mesenchymal transition in breast cancer relates to the basal - like phenotype . Cancer Res 68 : 989 – 997 , 2008 . 262 . Sasportas LS , Gambhir SS . Imaging circulating tumor cells in freely moving awake small animals using a miniaturized intravital microscope . PLoS One 9 : 2014 . 263 . Scheel C , Eaton EN , Li SH , Chaffer CL , Reinhardt F , Kah KJ , Bell G , Guo W , Rubin J , Richardson AL , Weinberg RA . Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast . Cell 145 : 926 – 940 , 2011 . 265 . Scheel C , Weinberg RA . Cancer stem cells and epithelial - mesenchymal transition : concepts and molecular links . Sem Cancer Biol 22 : 396 – 403 , 2012 . 266 . Schliekelman MJ , Gibbons DL , Faca VM , Creighton CJ , Rizvi ZH , Zhang Q , Wong CH , Wang H , Ungewiss C , Ahn YH , Shin DH , Kurie JM , Hanash SM . Targets of the tumor suppressor miR - 200 in regulation of the epithelial - mesenchymal transition in cancer . Cancer Res 71 : 7670 – 7682 , 2011 . 267 . Schultz EM , Silvestri GA , Gould MK . Variation in experts’ beliefs about lung cancer growth , progression , and prognosis . J Thorac Oncol 3 : 422 – 426 , 2008 . 268 . Segal E , Friedman N , Koller D , Regev A . A module map showing conditional activity of expression modules in cancer . Nat Genet 36 : 1090 – 1098 , 2004 . 269 . Sequist LV , Waltman BA , Dias - Santagata D , Digumarthy S , Turke AB , Fidias P , Bergethon K , Shaw AT , Gettinger S , Cosper AK , Akhavanfard S , Heist RS , Temel J , Christensen JG , Wain JC , Lynch TJ , Vernovsky K , Mark EJ , Lanuti M , Iafrate AJ , Mino - Kenudson M , Engelman JA . Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors . Sci Transl Med 3 : 75ra26 , 2011 . 270 . Shackelford DB , Abt E , Gerken L , Vasquez DS , Seki A , Leblanc M , Wei L , Fishbein MC , Czernin J , Mischel PS , Shaw RJ . LKB1 inactivation dictates therapeutic response of non - small cell lung cancer to the metabolism drug phenformin . Cancer Cell 23 : 143 – 158 , 2013 . 271 . Shamir ER , Pappalardo E , Jorgens DM , Coutinho K , Tsai WT , Aziz K , Auer M , Tran PT , Bader JS , Ewald AJ . Twist1 - induced dissemi - nation preserves epithelial identity and requires E - cadherin . J Cell Biol 204 : 839 – 856 , 2014 . 272 . Shang X , Marchioni F , Sipes N , Evelyn CR , Jerabek - Willemsen M , Duhr S , Seibel W , Wortman M , Zheng Y . Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases . Chem Biol 19 : 699 – 710 , 2012 . 273 . Shannon P , Markiel A , Ozier O , Baliga NS , Wang JT , Ramage D , Amin N , Schwikowski B , Ideker T . Cytoscape : a software environment for integrated models of biomolecular interaction networks . Genome Res 13 : 2498 – 2504 , 2003 . 274 . Shapiro E , Biezuner T , Linnarsson S . Single - cell sequencing - based technologies will revolutionize whole - organism science . Nat Rev Genet 14 : 618 – 630 , 2013 . 275 . Shapiro IM , Cheng AW , Flytzanis NC , Balsamo M , Condeelis JS , Oktay MH , Burge CB , Gertler FB . An EMT - driven alternative splicing program occurs in human breast cancer and modulates cellular pheno - type . PLoS Genet 7 : e1002218 , 2011 . 276 . Shaw AT , Kim DW , Mehra R , Tan DS , Felip E , Chow LQ , Camidge DR , Vansteenkiste J , Sharma S , De Pas T , Riely GJ , Solomon BJ , Wolf J , Thomas M , Schuler M , Liu G , Santoro A , Lau YY , Gold - wasser M , Boral AL , Engelman JA . Ceritinib in ALK - rearranged non - small - cell lung cancer . N Engl J Med 370 : 1189 – 1197 , 2014 . 277 . Shi Y , Massague J . Mechanisms of TGF - beta signaling from cell membrane to the nucleus . Cell 113 : 685 – 700 , 2003 . 278 . Shintani Y , Abulaiti A , Kimura T , Funaki S , Nakagiri T , Inoue M , Sawabata N , Minami M , Morii E , Okumura M . Pulmonary ﬁbroblasts induce epithelial mesenchymal transition and some characteristics of stem cells in non - small cell lung cancer . Ann Thorac Surg 96 : 425 – 433 , 2013 . 279 . Shirayoshi Y , Nose A , Iwasaki K , Takeichi M . N - linked oligosaccha - rides are not involved in the function of a cell - cell binding glycoprotein E - cadherin . Cell Struct Funct 11 : 245 – 252 , 1986 . 280 . Shrager J , Tenenbaum JM . Rapid learning for precision oncology . Nat Rev Clin Oncol 11 : 109 – 118 , 2014 . 281 . Shukla A , Edwards R , Yang Y , Hahn A , Folkers K , Ding J , Padma - kumar VC , Cataisson C , Suh KS , Yuspa SH . CLIC4 regulates TGF - beta - dependent myoﬁbroblast differentiation to produce a cancer stroma . Oncogene 33 : 842 – 850 , 2014 . 282 . Siegelin MD , Borczuk AC . Epidermal growth factor receptor mutations in lung adenocarcinoma . Lab Invest 94 : 129 – 137 , 2014 . 283 . Sim SC , Altman RB , Ingelman - Sundberg M . Databases in the area of pharmacogenetics . Hum Mutat 32 : 526 – 531 , 2011 . 284 . Simon R . Bioinformatics in cancer therapeutics—hype or hope ? Nat Oncol 2 : 223 , 2005 . 285 . Singh A , Settleman J . EMT , cancer stem cells and drug resistance : an emerging axis of evil in the war on cancer . Oncogene 29 : 4741 – 4751 , 2010 . 286 . Singh M , Cowell L , Seo S , O’Neill G , Golemis E . Molecular basis for HEF1 / NEDD9 / Cas - L action as a multifunctional co - ordinator of inva - sion , apoptosis and cell cycle . Cell Biochem Biophys 48 : 54 – 72 , 2007 . 287 . Singh MK , Izumchenko E , Klein - Szanto AJ , Egleston BL , Wolfson M , Golemis EA . Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9 . Cancer Res 70 : 8907 – 8916 , 2010 . 289 . Sørlie T , Tibshirani R , Parker J , Hastie T , Marron JS , Nobel A , Deng S , Johnsen H , Pesich R , Geisler S , Demeter J , Perou CM , Lønning PE , Brown PO , Børresen - Dale AL , Botstein D . Repeated observation of breast tumor subtypes in independent gene expression data sets . Proc Natl Acad Sci USA 100 : 8418 – 8423 , 2003 . 290 . Subramanian A , Tamayo P , Mootha VK , Mukherjee S , Ebert BL , Gillette MA , Paulovich A , Pomeroy SL , Golub TR , Lander ES , Mesirov JP . Gene set enrichment analysis : a knowledge - based approach for interpreting genome - wide expression proﬁles . Proc Natl Acad Sci USA 102 : 15545 – 15550 , 2005 . 291 . Swanton C . My Cancer Genome : a uniﬁed genomics and clinical trial portal . Lancet Oncol 13 : 668 – 669 , 2012 . 292 . Takai E , Tsukimoto M , Harada H , Sawada K , Moriyama Y , Kojima S . Autocrine regulation of TGF - beta 1 - induced cell migration by exocy - tosis of ATP and activation of P2 receptors in human lung cancer cells . J Cell Sci 125 : 5051 – 5060 , 2012 . 293 . Tam WL , Weinberg RA . The epigenetics of epithelial - mesenchymal plasticity in cancer . Nat Med 19 : 1438 – 1449 , 2013 . 294 . Tan DS , Camilleri - Broet S , Tan EH , Alifano M , Lim WT , Bobbio A , Zhang S , Ng QS , Ang MK , Iyer NG , Takano A , Lim KH , Regnard JF , Tan P , Broet P . Intertumor heterogeneity of non - small - cell lung carcinomas revealed by multiplexed mutation proﬁling and integrative genomics . Int J Cancer 135 : 1092 – 1100 , 2014 . 295 . Tarraga J , Medina I , Carbonell J , Huerta - Cepas J , Minguez P , Alloza E , Al - Shahrour F , Vegas - Azcarate S , Goetz S , Escobar P , Garcia - Garcia F , Conesa A , Montaner D , Dopazo J . GEPAS , a web - based tool for microarray data analysis and interpretation . Nucleic Acids Res 36 : W308 – W314 , 2008 . 296 . Theys J , Jutten B , Habets R , Paesmans K , Groot AJ , Lambin P , Wouters BG , Lammering G , Vooijs M . E - Cadherin loss associated with EMT promotes radioresistance in human tumor cells . Radiother Oncol 99 : 392 – 397 , 2011 . 297 . Thiery JP . Epithelial - mesenchymal transitions in tumour progression . Nat Rev Cancer 2 : 442 – 454 , 2002 . 298 . Thiery JP , Acloque H , Huang RY , Nieto MA . Epithelial - mesenchymal transitions in development and disease . Cell 139 : 871 – 890 , 2009 . 299 . Thiery JP , Sleeman JP . Complex networks orchestrate epithelial - mes - enchymal transitions . Nat Rev Mol Cell Biol 7 : 131 – 142 , 2006 . 300 . Thorn CF , Klein TE , Altman RB . Pharmacogenomics and bioinfor - matics : PharmGKB . Pharmacogenomics 11 : 501 – 505 , 2010 . Review 722 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m 301 . Thorvaldsdottir H , Robinson JT , Mesirov JP . Integrative Genomics Viewer ( IGV ) : high - performance genomics data visualization and explo - ration . Brief Bioinformat 14 : 178 – 192 , 2013 . 302 . Tibes R , Qiu Y , Lu Y , Hennessy B , Andreeff M , Mills GB , Kornblau SM . Reverse phase protein array : validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells . Mol Cancer Ther 5 : 2512 – 2521 , 2006 . 303 . Tikhmyanova N , Golemis EA . NEDD9 and BCAR1 negatively regulate E - cadherin membrane localization , and promote E - cadherin degradation . PLoS One 6 : e22102 , 2011 . 304 . Tikhmyanova N , Little JL , Golemis EA . CAS proteins in normal and pathological cell growth control . Cell Mol Life Sci 67 : 1025 – 1048 , 2010 . 305 . Tikhmyanova N , Tulin AV , Roegiers F , Golemis EA . Dcas supports cell polarization and cell - cell adhesion complexes in development . PLoS One 5 : e12369 , 2010 . 306 . Tirino V , Camerlingo R , Bifulco K , Irollo E , Montella R , Paino F , Sessa G , Carriero MV , Normanno N , Rocco G , Pirozzi G . TGF - (cid:2) 1 exposure induces epithelial to mesenchymal transition both in CSCs and non - CSCs of the A549 cell line , leading to an increase of migration ability in the CD133 (cid:6) A549 cell fraction . Cell Death Dis 4 : e620 , 2013 . 307 . Tiseo M , Rossi G , Capelletti M , Sartori G , Spiritelli E , Marchioni A , Bozzetti C , De Palma G , Lagrasta C , Campanini N , Camisa R , Boni L , Franciosi V , Rindi G , Ardizzoni A . Predictors of geﬁtinib outcomes in advanced non - small cell lung cancer ( NSCLC ) : study of a compre - hensive panel of molecular markers . Lung Cancer 67 : 355 – 360 , 2010 . 308 . Toiyama Y , Yasuda H , Saigusa S , Matushita K , Fujikawa H , Tanaka K , Mohri Y , Inoue Y , Goel A , Kusunoki M . Co - expression of hepa - tocyte growth factor and c - Met predicts peritoneal dissemination estab - lished by autocrine hepatocyte growth factor / c - Met signaling in gastric cancer . Int J Cancer 130 : 2912 – 2921 , 2012 . 309 . Tomida S , Takeuchi T , Shimada Y , Arima C , Matsuo K , Mitsudomi T , Yatabe Y , Takahashi T . Relapse - related molecular signature in lung adenocarcinomas identiﬁes patients with dismal prognosis . J Clin Oncol 27 : 2793 – 2799 , 2009 . 310 . Tran DD , Corsa CA , Biswas H , Aft RL , Longmore GD . Temporal and spatial cooperation of Snail1 and Twist1 during epithelial - mesenchymal transition predicts for human breast cancer recurrence . Mol Cancer Res 9 : 1644 – 1657 , 2011 . 311 . Tsai JH , Donaher JL , Murphy DA , Chau S , Yang J . Spatiotemporal regulation of epithelial - mesenchymal transition is essential for squamous cell carcinoma metastasis . Cancer Cell 22 : 725 – 736 , 2012 . 312 . Tsai JH , Yang J . Epithelial - mesenchymal plasticity in carcinoma me - tastasis . Genes Dev 27 : 2192 – 2206 , 2013 . 313 . Tsimberidou AM , Iskander NG , Hong DS , Wheler JJ , Falchook GS , Fu S , Piha - Paul S , Naing A , Janku F , Luthra R , Ye Y , Wen S , Berry D , Kurzrock R . Personalized medicine in a phase I clinical trials program : the MD Anderson Cancer Center initiative . Clin Cancer Res 18 : 6373 – 6383 , 2012 . 314 . Tsimberidou AM , Wen S , Hong DS , Wheler JJ , Falchook GS , Fu S , Piha - Paul SA , Naing A , Janku F , Aldape KD , Ye Y , Kurzrock R , Berry DA . Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson : validation and landmark analyses . Clin Cancer Res [ Epub ahead of print ] . 315 . Tsuji T , Ibaragi S , Shima K , Hu MG , Katsurano M , Sasaki A , Hu GF . Epithelial - mesenchymal transition induced by growth suppressor p12CDK2 - AP1 promotes tumor cell local invasion but suppresses distant colony growth . Cancer Res 68 : 10377 – 10386 , 2008 . 316 . Turke AB , Zejnullahu K , Wu YL , Song Y , Dias - Santagata D , Lifshits E , Toschi L , Rogers A , Mok T , Sequist L , Lindeman NI , Murphy C , Akhavanfard S , Yeap BY , Xiao Y , Capelletti M , Iafrate AJ , Lee C , Christensen JG , Engelman JA , Janne PA . Preexistence and clonal selection of MET ampliﬁcation in EGFR mutant NSCLC . Cancer Cell 17 : 77 – 88 , 2010 . 317 . Valenta T , Hausmann G , Basler K . The many faces and functions of beta - catenin . EMBO J 31 : 2714 – 2736 , 2012 . 318 . van Roy F . Beyond E - cadherin : roles of other cadherin superfamily members in cancer . Nat Rev Cancer 14 : 121 – 134 , 2014 . 319 . van Roy F , Berx G . The cell - cell adhesion molecule E - cadherin . Cell Mol Life Sci 65 : 3756 – 3788 , 2008 . 320 . van Zijl F , Mair M , Csiszar A , Schneller D , Zulehner G , Huber H , Eferl R , Beug H , Dolznig H , Mikulits W . Hepatic tumor - stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge . Oncogene 28 : 4022 – 4033 , 2009 . 321 . Vaquerizas JM , Conde L , Yankilevich P , Cabezon A , Minguez P , Diaz - Uriarte R , Al - Shahrour F , Herrero J , Dopazo J . GEPAS , an experiment - oriented pipeline for the analysis of microarray gene expres - sion data . Nucleic Acids Res 33 : W616 – W620 , 2005 . 322 . Vignot S , Frampton GM , Soria JC , Yelensky R , Commo F , Bram - billa C , Palmer G , Moro - Sibilot D , Ross JS , Cronin MT , Andre F , Stephens PJ , Lazar V , Miller VA , Brambilla E . Next - generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non - small - cell lung cancer . J Clin Oncol 31 : 2167 – 2172 , 2013 . 323 . Villarejo A , Cortes - Cabrera A , Molina - Ortiz P , Portillo F , Cano A . Differential role of Snail1 and Snail2 zinc ﬁngers in E - cadherin repres - sion and epithelial to mesenchymal transition . J Biol Chem 289 : 930 – 941 , 2014 . 324 . Vogelstein B , Papadopoulos N , Velculescu VE , Zhou S , Diaz LA Jr , Kinzler KW . Cancer genome landscapes . Science 339 : 1546 – 1558 , 2013 . 325 . von Mering C , Jensen LJ , Snel B , Hooper SD , Krupp M , Foglierini M , Jouffre N , Huynen MA , Bork P . STRING : known and predicted protein - protein associations , integrated and transferred across organisms . Nucleic Acids Res 33 : D433 – D437 , 2005 . 326 . Warzecha CC , Carstens RP . Complex changes in alternative pre - mRNA splicing play a central role in the epithelial - to - mesenchymal transition ( EMT ) . Sem Cancer Biol 22 : 417 – 427 , 2012 . 327 . Warzecha CC , Jiang P , Amirikian K , Dittmar KA , Lu HZ , Shen SH , Guo W , Xing Y , Carstens RP . An ESRP - regulated splicing programme is abrogated during the epithelial - mesenchymal transition . EMBO J 29 : 3286 – 3300 , 2010 . 328 . Wei Z . Hidden Markov models for controlling false discovery rate in genome - wide association analysis . Meth Mol Biol 802 : 337 – 344 , 2012 . 329 . Weinberg RA . Moving out : invasion and metastasis . In : The Biology of Cancer , edited by Schanck D . New York : Garland Science , 2013 , p . 641 – 721 . 330 . Wheeler HE , Maitland ML , Dolan ME , Cox NJ , Ratain MJ . Cancer pharmacogenomics : strategies and challenges . Nat Rev Genet 14 : 23 – 34 , 2013 . 331 . Whirl - Carrillo M , McDonagh EM , Hebert JM , Gong L , Sangkuhl K , Thorn CF , Altman RB , Klein TE . Pharmacogenomics knowledge for personalized medicine . Clin Pharmacol Ther 92 : 414 – 417 , 2012 . 332 . Wu Y , Liu HB , Ding M , Liu JN , Zhan P , Fu XS , Lu G . The impact of E - cadherin expression on non - small cell lung cancer survival : a meta - analysis . Mol Biol Rep 39 : 9621 – 9628 , 2012 . 333 . Xi Y , Wei Y , Sennino B , Ulsamer A , Kwan I , Brumwell AN , Tan K , Aghi MK , McDonald DM , Jablons DM , Chapman HA . Identiﬁcation of pY654 - beta - catenin as a critical co - factor in hypoxia - inducible factor - 1alpha signaling and tumor responses to hypoxia . Oncogene 32 : 5048 – 5057 , 2013 . 334 . Xiao D , He J . Epithelial mesenchymal transition and lung cancer . J Thorac Dis 2 : 154 – 159 , 2010 . 335 . Xie D , Gore C , Liu J , Pong RC , Mason R , Hao G , Long M , Kabbani W , Yu L , Zhang H , Chen H , Sun X , Boothman DA , Min W , Hsieh JT . Role of DAB2IP in modulating epithelial - to - mesenchymal transition and prostate cancer metastasis . Proc Natl Acad Sci USA 107 : 2485 – 2490 , 2010 . 336 . Yaffe MB . The scientiﬁc drunk and the lamppost : massive sequencing efforts in cancer discovery and treatment . Sci Signal 6 : pe13 , 2013 . 337 . Yamaguchi N , VanderLaan PA , Folch E , Boucher DH , Canepa HM , Kent MS , Gangadharan SP , Majid A , Kocher ON , Goldstein MA , Huberman MS , Costa DB . Smoking status and self - reported race affect the frequency of clinically relevant oncogenic alterations in non - small - cell lung cancers at a United States - based academic medical practice . Lung Cancer 82 : 31 – 37 , 2013 . 338 . Yan PS , Potter D , Deatherage DE , Huang TH , Lin S . Differential methylation hybridization : proﬁling DNA methylation with a high - density CpG island microarray . Meth Mol Biol 507 : 89 – 106 , 2009 . 339 . Yang CY , Chang CH , Yu YL , Lin TC , Lee SA , Yen CC , Yang JM , Lai JM , Hong YR , Tseng TL , Chao KM , Huang CY . PhosphoPOINT : a comprehensive human kinase interactome and phospho - protein data - base . Bioinformatics 24 : i14 – i20 , 2008 . 340 . Yang MH , Wu MZ , Chiou SH , Chen PM , Chang SY , Liu CJ , Teng SC , Wu KJ . Direct regulation of TWIST by HIF - 1alpha promotes metastasis . Nat Cell Biol 10 : 295 – 305 , 2008 . 341 . Yang P . Epidemiology of lung cancer prognosis : quantity and quality of life . Meth Mol Biol 471 : 469 – 486 , 2009 . Review 723 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m 342 . YangW , SoaresJ , GreningerP , EdelmanEJ , LightfootH , ForbesS , Bindal N , Beare D , Smith JA , Thompson IR , Ramaswamy S , Futreal PA , Haber DA , Stratton MR , Benes C , McDermott U , Garnett MJ . Genomics of Drug Sensitivity in Cancer ( GDSC ) : a resource for therapeutic biomarker discov - ery in cancer cells . Nucleic Acids Res 41 : D955 – D961 , 2013 . 343 . Yoo SB , Kim YJ , Kim H , Jin Y , Sun PL , Jheon S , Lee JS , Chung JH . Alteration of the E - cadherin / beta - catenin complex predicts poor response to epidermal growth factor receptor - tyrosine kinase inhibitor ( EGFR - TKI ) treatment . Ann Surg Oncol 20 , Suppl 3 : S545 – S552 , 2013 . 344 . Yu M , Bardia A , Wittner B , Stott SL , Smas ME , Ting DT , Isakoff SJ , Ciciliano JC , Wells MN , Shah AM , Concannon KF , Donaldson MC , Sequist LV , Brachtel E , Sgroi D , Baselga J , Ramaswamy S , Toner M , Haber DA , Maheswaran S . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition . Science 339 : 580 – 584 , 2013 . 346 . Yuan J , Liu Y , Wang Y , Xie G , Blevins R . Genome analysis with gene - indexing databases . Pharmacol Therapeut 91 : 115 – 132 , 2001 . 347 . Zeisberg M , Neilson EG . Biomarkers for epithelial - mesenchymal tran - sitions . J Clin Invest 119 : 1429 – 1437 , 2009 . 348 . Zhang J , Ma L . MicroRNA control of epithelial - mesenchymal transition and metastasis . Cancer Metastas Rev 31 : 653 – 662 , 2012 . 349 . Zuberi K , Franz M , Rodriguez H , Montojo J , Lopes CT , Bader GD , Morris Q . GeneMANIA Prediction Server 2013 Update . Nucleic Acids Res 41 : W115 – W122 , 2013 . Review 724 APPLYING BIOINFORMATICS TO STUDY EMT IN LUNG CANCER Physiol Genomics • doi : 10 . 1152 / physiolgenomics . 00062 . 2014 • www . physiolgenomics . org b y 10 . 220 . 33 . 6 on N o v e m be r 15 , 2017 h tt p : / / ph ys i o l geno m i cs . ph ys i o l og y . o r g / D o w n l oaded f r o m